Loading organization details...
Loading organization details...
TO IMPROVE THE WORLD THROUGH RESEARCH, SCHOLARSHIP, EDUCATION, PRESERVATION, AND PRACTICE.
Source: IRS Form 990 (Tax Year 2024)
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2023
Total Revenue
▼$6.8B
Program Spending
86%
of total expenses go to program services
Total Contributions
$1.4B
Total Expenses
▼$6.2B
Total Assets
$55.2B
Total Liabilities
▼$10B
Net Assets
$45.2B
Officer Compensation
→$15.5M
Other Salaries
$2.5B
Investment Income
$2.4B
Fundraising
▼$409.1K
Tax Year 2023 · Source: IRS Form 990, Schedule I (Grants and Other Assistance)
Total grants awarded: $137.2M
| Recipient | Location | Amount | Type | Purpose |
|---|---|---|---|---|
UNIVERSITY OF CALIFORNIA SAN DIEGO95-6006144 | LA JOLLA, CA | $6.5M | Cash | SUBAWARD - SPONSORED RESEARCH |
NEW HAVEN PROMISE INC81-1267064 | NEW HAVEN, CT | $4.4M | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $3.7M | Cash | SUBAWARD - SPONSORED RESEARCH |
| NEW YORK, NY | $3.3M | Cash | SUBAWARD - SPONSORED RESEARCH | |
| PHILADELPHIA, PA | $3.2M | Cash | SUBAWARD - SPONSORED RESEARCH | |
VANDERBILT UNIVERSITY MEDICAL CENTER35-2528741 | NASHVILLE, TN | $2.8M | Cash | SUBAWARD - SPONSORED RESEARCH |
DUKE UNIVERSITY56-0532129 | DURHAM, NC | $2.8M | Cash | SUBAWARD - SPONSORED RESEARCH |
NEW YORK UNIVERSITY13-5562308 | NEW YORK, NY | $2.4M | Cash | SUBAWARD - SPONSORED RESEARCH |
CHILDREN'S HOSPITAL CORPORATION | BOSTON, MA | $2.4M | Cash | SUBAWARD - SPONSORED RESEARCH |
| DALLAS, TX | $2.3M | Cash | SUBAWARD - SPONSORED RESEARCH | |
UNIVERSITY OF MASSACHUSETTS | BOSTON, MA | $2.3M | Cash | SUBAWARD - SPONSORED RESEARCH |
MAYO CLINIC41-6011702 | ROCHESTER, MN | $2.2M | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF CINCINNATI31-6000989 | CINCINNATI, OH | $2M | Cash | SUBAWARD - SPONSORED RESEARCH |
BRIGHAM AND WOMEN'S HOSPITAL INC | BOSTON, MA | $2M | Cash | SUBAWARD - SPONSORED RESEARCH |
CARBON CONTAINMENT LAB93-4853247 | NEW HAVEN, CT | $2M | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
STANFORD UNIVERSITY94-1156365 | REDWOOD CITY, CA | $2M | Cash | SUBAWARD - SPONSORED RESEARCH |
PRESIDENT AND FELLOWS OF HARVARD COLLEGE | CAMBRIDGE, MA | $1.9M | Cash | SUBAWARD - SPONSORED RESEARCH |
JOHNS HOPKINS UNIVERSITY52-0595110 | BALTIMORE, MD | $1.9M | Cash | SUBAWARD - SPONSORED RESEARCH |
WASHINGTON UNIVERSITY43-0653611 | ST LOUIS, MO | $1.7M | Cash | SUBAWARD - SPONSORED RESEARCH |
| CHAPEL HILL, NC | $1.7M | Cash | SUBAWARD - SPONSORED RESEARCH | |
UNIVERSITY OF ALABAMA AT BIRMINGHAM63-6005396 | BIRMINGHAM, AL | $1.7M | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF CALIFORNIA LOS ANGELES95-6006143 | LOS ANGELES, CA | $1.7M | Cash | SUBAWARD - SPONSORED RESEARCH |
| NEW YORK, NY | $1.6M | Cash | SUBAWARD - SPONSORED RESEARCH | |
MCLEAN HOSPITAL CORPORATION | BOSTON, MA | $1.5M | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF WASHINGTON91-6001537 | SEATTLE, WA | $1.4M | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF PITTSBURGH25-0965591 | PITTSBURGH, PA | $1.4M | Cash | SUBAWARD - SPONSORED RESEARCH |
EMORY UNIVERSITY58-0566256 | ATLANTA, GA | $1.4M | Cash | SUBAWARD - SPONSORED RESEARCH |
| ATHENS, GA | $1.3M | Cash | SUBAWARD - SPONSORED RESEARCH | |
BETH ISRAEL DEACONESS MEDICAL CENTER INC | BOSTON, MA | $1.3M | Cash | SUBAWARD - SPONSORED RESEARCH |
HARTFORD HOSPITAL | HARTFORD, CT | $1.3M | Cash | SUBAWARD - SPONSORED RESEARCH |
YALE NEW HAVEN HOSPITAL | NEW HAVEN, CT | $1.3M | Cash | DAF DISTRIBUTION |
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI13-6171197 | NEW YORK, NY | $1.3M | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF CALIFORNIA IRVINE95-2226406 | IRVINE, CA | $1.2M | Cash | SUBAWARD - SPONSORED RESEARCH |
| ALBANY, NY | $1.2M | Cash | SUBAWARD - SPONSORED RESEARCH | |
| SAN FRANCISCO, CA | $1.2M | Cash | SUBAWARD - SPONSORED RESEARCH | |
| HOUSTON, TX | $1.1M | Cash | SUBAWARD - SPONSORED RESEARCH | |
ALAMEDA HEALTH SYSTEM94-3302014 | SAN FRANCISCO, CA | $1.1M | Cash | SEE PART IV |
| DENVER, CO | $1.1M | Cash | SUBAWARD - SPONSORED RESEARCH | |
FRIENDS OF THE ISRAEL DEFENSE FORCES13-3156445 | NEW YORK, NY | $1M | Cash | DAF DISTRIBUTION |
| WESTBURY, NY | $972.9K | Cash | SUBAWARD - SPONSORED RESEARCH | |
TEMPLE UNIVERSITY23-1365971 | PHILADELPHIA, PA | $954.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
NORTHWESTERN UNIVERSITY36-2167817 | EVANSTON, IL | $943.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
TRAJECTORY OF HOPE LLC83-0709336 | LOS ANGELES, CA | $919.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE URBAN ASSEMBLY INC11-0332039 | NEW YORK, NY | $868.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
MEDICAL UNIVERSITY OF SOUTH CAROLINA57-6000722 | CHARLESTON, SC | $859K | Cash | SUBAWARD - SPONSORED RESEARCH |
CORNELL UNIVERSITY15-0532082 | ITHACA, NY | $851.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF FLORIDA59-6002052 | GAINESVILLE, FL | $844.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
| WEST HAVEN, CT | $813.5K | Cash | SUBAWARD - SPONSORED RESEARCH | |
UNIVERSITY OF WISCONSIN SYSTEM39-6006492 | MADISON, WI | $812K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF MIAMI59-0624458 | CORAL GABLES, FL | $811.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
APT FOUNDATION INC23-7061218 | NEW HAVEN, CT | $776.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
GEORGETOWN UNIVERSITY53-0196603 | WASHINGTON, DC | $749.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
SEATTLE CHILDREN'S HOSPITAL91-0564748 | SEATTLE, WA | $735.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
BOSTON MEDICAL CENTER CORPORATION | BOSTON, MA | $713K | Cash | SUBAWARD - SPONSORED RESEARCH |
HENNEPIN HEALTHCARE RESEARCH INSTITUTE41-1677920 | MINNEAPOLIS, MN | $679.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF CHICAGO36-2177139 | CHICAGO, IL | $677.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
| SAN FRANCISCO, CA | $671.6K | Cash | SUBAWARD - SPONSORED RESEARCH | |
UNIVERSITY OF CONNECTICUT | STORRS, CT | $651.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
CHILDREN'S HOSPITAL LOS ANGELES95-1690977 | LOS ANGELES, CA | $638.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF CONNECTICUT HEALTH52-1725543 | FARMINGTON, CT | $637.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF MISSOURI KANSAS CITY43-6003859 | KANSAS CITY, MO | $612K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF NEW MEXICO85-6000642 | ALBUQUERQUE, NM | $608.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF UTAH87-6000525 | SALT LAKE CITY, UT | $590.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
SENTARA HEALTH52-1271901 | VIRGINIA BEACH, VA | $579.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
REGENTS OF THE UNIVERSITY OF MINNESOTA41-6007513 | MINNEAPOLIS, MN | $577.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
CONTINUUM OF CARE INC | NEW HAVEN, CT | $568.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE CHILDREN'S HOSPITAL OF PHILADELPHIA23-1352166 | PHILADELPHIA, PA | $550.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
BROWN UNIVERSITY | PROVIDENCE, RI | $543.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
TEXAS CHRISTIAN UNIVERSITY75-0827465 | FORT WORTH, TX | $529.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
ALBERT EINSTEIN COLLEGE OF MEDICINE83-0621846 | BRONX, NY | $526K | Cash | SEE PART IV |
REGENTS OF THE UNIVERSITY OF MICHIGAN38-6006309 | ANN ARBOR, MI | $522.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
RUTGERS THE STATE UNIVERSITY22-6001086 | PISCATAWAY, NJ | $515.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE JACKSON LABORATORY | BAR HARBOR, ME | $501K | Cash | SUBAWARD - SPONSORED RESEARCH |
| HOUSTON, TX | $500K | Cash | DAF DISTRIBUTION | |
HEARTS FOR HEARING FOUNDATION58-2670613 | OKLAHOMA CITY, OK | $495.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE UNIVERSITY OF TEXAS AT AUSTIN74-6000203 | AUSTIN, TX | $493.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
AMERICAN UNIVERSITY OF BEIRUT13-5596846 | NEW YORK, NY | $492.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
WEST VIRGINIA UNIVERSITY55-6000842 | MORGANTOWN, WV | $485.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
HEALTH RESEARCH INC14-1402155 | MENANDS, NY | $481.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF SOUTHERN CALIFORNIA95-1642394 | LOS ANGELES, CA | $468.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
VAN ANDEL RESEARCH INSTITUTE52-2000823 | GRAND RAPIDS, MI | $468.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
GRIFFIN HOSPITAL | DERBY, CT | $467.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE OHIO STATE UNIVERSITY31-6025986 | COLUMBUS, OH | $465.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
ST JUDE CHILDREN'S RESEARCH HOSPITAL INC62-0646012 | MEMPHIS, TN | $449.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
TRUSTEES OF BOSTON UNIVERSITY | BOSTON, MA | $448.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
KAISER FOUNDATION HOSPITALS94-1105628 | OAKLAND, CA | $446.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
LATHAM BIOPHARM GROUP INC | ELKRIDGE, MD | $434.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE PENNSYLVANIA STATE UNIVERSITY24-6000376 | STATE COLLEGE, PA | $424.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
UIH AMERICA INC46-2408342 | HOUSTON, TX | $423.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
MAINEHEALTH | PORTLAND, ME | $415.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
JOSEPH SLIFKA CENTER FOR JEWISH LIFE AT YALE | NEW HAVEN, CT | $404.5K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
UNIVERSITY OF MARYLAND52-6002033 | COLLEGE PARK, MD | $404.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF VIRGINIA54-6001796 | CHARLOTTESVILLE, VA | $402.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
FOX CHASE CANCER CENTER FOUNDATION23-2003072 | PHILADELPHIA, PA | $391.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
VANDERBILT UNIVERSITY62-0476822 | NASHVILLE, TN | $386.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
| NEW YORK, NY | $375.1K | Cash | SUBAWARD - SPONSORED RESEARCH | |
DANA-FARBER CANCER INSTITUTE INC | BOSTON, MA | $368.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
| LA JOLLA, CA | $366.1K | Cash | SUBAWARD - SPONSORED RESEARCH | |
UNIVERSITY OF CALIFORNIA DAVIS94-6036494 | DAVIS, CA | $359.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF CALIFORNIA SANTA BARBARA95-6006145 | SANTA BARBARA, CA | $359.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
| PHOENIX, AZ | $349.4K | Cash | SUBAWARD - SPONSORED RESEARCH | |
UNIVERSITY OF PUERTO RICO66-0433760 | SAN JUAN, PR | $345K | Cash | SUBAWARD - SPONSORED RESEARCH |
STATE OF CONNECTICUT | HARTFORD, CT | $340.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF ROCHESTER16-0743209 | ROCHESTER, NY | $335.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
AMERICAN NATIONAL RED CROSS53-0196605 | WASHINGTON, DC | $318.2K | Cash | SEE PART IV |
THE UNIVERSITY OF RHODE ISLAND | KINGSTON, RI | $314.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
| SAN JUAN, PR | $307.2K | Cash | SUBAWARD - SPONSORED RESEARCH | |
UNIVERSITY OF CALIFORNIA BERKELEY94-6002123 | BERKELEY, CA | $306.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
MICHIGAN STATE UNIVERSITY38-6005984 | EAST LANSING, MI | $305.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
CASE WESTERN RESERVE UNIVERSITY34-1018992 | CLEVELAND, OH | $300.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
BRIDGES HEALTHCARE INC | MILFORD, CT | $299K | Cash | SUBAWARD - SPONSORED RESEARCH |
PRISMA HEALTH-UPSTATE81-1723202 | GREENVILLE, SC | $298.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
NORTHEASTERN UNIVERSITY | BOSTON, MA | $295.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
HPM FOUNDATION INC66-0437924 | SAN JUAN, PR | $291.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE COOPER HEALTH SYSTEM21-0634462 | CAMDEN, NJ | $290.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
CHILDREN'S RESEARCH INSTITUTE52-1654453 | WASHINGTON, DC | $282.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
INDIANA UNIVERSITY35-6001673 | BLOOMINGTON, IN | $279.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
| KANSAS CITY, KS | $270.8K | Cash | SUBAWARD - SPONSORED RESEARCH | |
THE BROAD INSTITUTE INC26-3428781 | CAMBRIDGE, MA | $266.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
FRED HUTCHINSON CANCER RESEARCH CENTER23-7156071 | SEATTLE, WA | $265.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF DENVER84-0404231 | DENVER, CO | $257.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
INTEL FEDERAL LLC26-2071828 | SANTA CLARA, CA | $254.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
C4 INNOVATIONS LLC87-0763049 | NEEDHAM, MA | $254.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
CICATELLI ASSOCIATES INC13-3020576 | NEW YORK, NY | $250.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
CLIMATEHAVEN INC92-0306841 | NEW HAVEN, CT | $250K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
UNIVERSITY OF OREGON46-4727800 | EUGENE, OR | $250K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF NEBRASKA47-0049123 | OMAHA, NE | $248.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
CEDARS-SINAI MEDICAL CENTER95-1644600 | LOS ANGELES, CA | $246.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
LA JOLLA INSTITUTE FOR IMMUNOLOGY33-0328688 | LA JOLLA, CA | $241.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY | CAMBRIDGE, MA | $240.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE GEORGE WASHINGTON UNIVERSITY53-0196584 | ASHBURN, VA | $238K | Cash | SUBAWARD - SPONSORED RESEARCH |
NEW HAVEN INTERNATIONAL FESTIVAL OF ARTS AND IDEAS INC | NEW HAVEN, CT | $237.5K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
ID INSIGHT INC27-4933181 | SAN FRANCISCO, CA | $232.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
TAMPA GENERAL HOSPITAL59-3458145 | TAMPA, FL | $231.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
| MENANDS, NY | $228K | Cash | SUBAWARD - SPONSORED RESEARCH | |
HENRY FORD HEALTH SYSTEM38-1357020 | DETROIT, MI | $217.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
CALIFORNIA INSTITUTE OF TECHNOLOGY95-1643307 | PASADENA, CA | $215.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
SCIENCE COMMUNICATION LAB INC47-2404616 | OAKLAND, CA | $215.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE JOHN B PIERCE LABORATORY INC | NEW HAVEN, CT | $215.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
URBAN COMMUNITY ALLIANCE INC | NEW HAVEN, CT | $212.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
MARKET NEW HAVEN INC | NEW HAVEN, CT | $206.3K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
CIENCIA PUERTO RICO INC66-0911980 | SAN JUAN, PR | $202.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
MARSHALL UNIVERSITY RESEARCH CORPORATION55-0683361 | HUNTINGTON, WV | $193.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE UNIVERSITY OF ARIZONA74-2652689 | TUCSON, AZ | $188.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE UNIVERSITY OF OKLAHOMA73-6017987 | OKLAHOMA CITY, OK | $183.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
ARIZONA STATE UNIVERSITY86-0196696 | TEMPE, AZ | $181.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE CLEVELAND CLINIC FOUNDATION34-0714585 | CLEVELAND, OH | $177.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
INNOVATIONS FOR POVERTY ACTION | WASHINGTON, DC | $166.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
LIBERATION PROGRAMS INC | BRIDGEPORT, CT | $164.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
URBAN LEAGUE OF SOUTHERN CT INC | NEW HAVEN, CT | $164.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
UT-BATTELLE LLC62-1788235 | OAK RIDGE, TN | $162.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
FLORIDA INTERNATIONAL UNIVERSITY65-0177616 | MIAMI, FL | $161K | Cash | SUBAWARD - SPONSORED RESEARCH |
PURDUE UNIVERSITY35-6002041 | WEST LAFAYETTE, IN | $159.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
NEW HAVEN WORKS INC46-2662124 | NEW HAVEN, CT | $159.4K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
| ST THOMAS, VI | $159.2K | Cash | SUBAWARD - SPONSORED RESEARCH | |
BUCKLEY INSTITUTE INC27-5131268 | NEW HAVEN, CT | $158.8K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
THE SCRIPPS RESEARCH INSTITUTE33-0435954 | LA JOLLA, CA | $155.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
| BETHESDA, MD | $154.4K | Cash | SUBAWARD - SPONSORED RESEARCH | |
CENTER FOR PROGRESSIVE RECOVERY46-4950987 | NEW HAVEN, CT | $153.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNITED WAY OF GREATER NEW HAVEN INC | NEW HAVEN, CT | $152.5K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
WEST CHESTER UNIVERSITY OF PENNSYLVANIA23-2417773 | WEST CHESTER, PA | $152.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF SOUTH FLORIDA59-3102112 | TAMPA, FL | $148.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE LIEBER INSTITUTE INC26-3690883 | BALTIMORE, MD | $147.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE TRUSTEES OF PRINCETON UNIVERSITY21-0634501 | PRINCETON, NJ | $146.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
CYTOASTRA LLC81-3656746 | LITTLE ROCK, AR | $143.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
SAN FRANCISCO STATE UNIVERSITY93-1137247 | SAN FRANCISCO, CA | $139K | Cash | SUBAWARD - SPONSORED RESEARCH |
| FALLS CHURCH, VA | $137.3K | Cash | SUBAWARD - SPONSORED RESEARCH | |
FAIR HAVEN COMMUNITY HEALTH CLINIC INC | NEW HAVEN, CT | $135.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
| SEATTLE, WA | $135.1K | Cash | SUBAWARD - SPONSORED RESEARCH | |
OREGON HEALTH & SCIENCE UNIVERSITY93-1176109 | PORTLAND, OR | $134.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
| WHITE RIVER JUNCTION, VT | $132.1K | Cash | SUBAWARD - SPONSORED RESEARCH | |
NATIONAL ACADEMY OF SCIENCES53-0196932 | WASHINGTON, DC | $129.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
| BLACKSBURG, VA | $125.5K | Cash | SUBAWARD - SPONSORED RESEARCH | |
NEXIMMUNE INC45-2518457 | GAITHERSBURG, MD | $124.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
| HOUSTON, TX | $124K | Cash | SUBAWARD - SPONSORED RESEARCH | |
VISAGE IMAGING INC37-1551308 | SAN DIEGO, CA | $122.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
STANLEY STREET TREATMENT & RESOURCES INC | FALL RIVER, MA | $117.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
MEMORIAL SLOAN-KETTERING CANCER CENTER13-1924236 | NEW YORK, NY | $117.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
| DECATUR, GA | $114.2K | Cash | SUBAWARD - SPONSORED RESEARCH | |
TRIAD NATIONAL SECURITY LLC82-3291283 | LOS ALAMOS, NM | $112.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
YALE LAW SCHOOL LEARNING CENTER INC | NEW HAVEN, CT | $110K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
GEORGE MASON UNIVERSITY54-0836354 | FAIRFAX, VA | $108.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS38-1888798 | DALLAS, TX | $100.3K | Cash | SEE PART IV |
DETROIT ZOOLOGICAL SOCIETY38-6027356 | ROYAL OAK, MI | $100.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
| PALO ALTO, CA | $100K | Cash | SUBAWARD - SPONSORED RESEARCH | |
ACHIEVEMENT FIRST INC65-1203744 | NEW HAVEN, CT | $100K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
TEACH FOR AMERICA INC13-3541913 | NEW YORK, NY | $100K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
THOMAS JEFFERSON UNIVERSITY23-1352651 | PHILADELPHIA, PA | $92.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
FREDERIKSTED HEALTH CARE INC66-0586667 | ST CROIX, VI | $88.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
RESEARCH TRIANGLE INSTITUTE56-0686338 | RESEARCH TRIANGLE PARK, NC | $87.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
WAYNE STATE UNIVERSITY38-6028429 | DETROIT, MI | $86.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
| SAN JUAN, PR | $84.8K | Cash | SUBAWARD - SPONSORED RESEARCH | |
THE WREXHAM FOUNDATION INC | NEW HAVEN, CT | $83.7K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
| LITTLE ROCK, AR | $81.8K | Cash | SUBAWARD - SPONSORED RESEARCH | |
THE NEW YORK STEM CELL FOUNDATION20-2905531 | NEW YORK, NY | $81.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
ROLLINS COLLEGE59-0624440 | WINTER PARK, FL | $81.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
ADVENTHEALTH ORLANDO59-0724459 | ORLANDO, FL | $80.2K | Cash | SEE PART IV |
LIBERTY COMMUNITY SERVICES22-2849124 | NEW HAVEN, CT | $80K | Cash | SUBAWARD - SPONSORED RESEARCH |
YALE UNIVERSITY DRAMATIC ASSOCIATION INC | NEW HAVEN, CT | $80K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
RENSSELAER POLYTECHNIC INSTITUTE14-1340095 | TROY, NY | $79.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF DELAWARE51-6000297 | NEWARK, DE | $79.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
SQUASH HAVEN INC20-5500876 | NEW HAVEN, CT | $79K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
INVICRO LLC26-3404955 | NEEDHAM, MA | $78.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
| HUDSON, NY | $78.7K | Cash | SUBAWARD - SPONSORED RESEARCH | |
COMMONSPIRIT HEALTH RESEARCH INSTITUTE27-1050565 | ENGLEWOOD, CO | $78.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
TUFTS UNIVERSITY | MEDFORD, MA | $77.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
| PHILADELPHIA, PA | $75K | Cash | SUBAWARD - SPONSORED RESEARCH | |
BAYLOR COLLEGE OF MEDICINE74-1613878 | HOUSTON, TX | $71.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
GEORGIA TECH RESEARCH CORPORATION58-0603146 | ATLANTA, GA | $71K | Cash | SUBAWARD - SPONSORED RESEARCH |
STATE UNIVERSITY OF IOWA42-6004813 | IOWA CITY, IA | $69.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
| BATON ROUGE, LA | $67.8K | Cash | SUBAWARD - SPONSORED RESEARCH | |
| ARLINGTON, VA | $66.1K | Cash | SEE PART IV | |
L2 DIAGNOSTICS LLC | WOODBRIDGE, CT | $64.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
CHILDREN'S HOSPITAL MEDICAL CENTER31-0833936 | CINCINNATI, OH | $64.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
DARTMOUTH-HITCHCOCK CLINIC22-2519596 | LEBANON, NH | $63K | Cash | SUBAWARD - SPONSORED RESEARCH |
RHODE ISLAND HOSPITAL | PROVIDENCE, RI | $61.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE MIRIAM HOSPITAL | PROVIDENCE, RI | $60.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
| URBANA, IL | $60.2K | Cash | SUBAWARD - SPONSORED RESEARCH | |
CATHOLIC MANAGED LONG TERM CARE INC20-8180809 | NEW YORK, NY | $59.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
HARVARD PILGRIM HEALTH CARE INC | CANTON, MA | $59.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF NOTRE DAME35-0868188 | NOTRE DAME, IN | $58.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
IQVIA INC | PARSIPPANY, NJ | $57K | Cash | SUBAWARD - SPONSORED RESEARCH |
| LAKEWOOD, CA | $53.6K | Cash | SUBAWARD - SPONSORED RESEARCH | |
COLORADO STATE UNIVERSITY84-6000545 | FORT COLLINS, CO | $53.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF RICHMOND54-0505965 | RICHMOND, VA | $51.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
| NEW HAVEN, CT | $51.4K | Cash | SUBAWARD - SPONSORED RESEARCH | |
EAST CAROLINA UNIVERSITY56-6000403 | GREENVILLE, NC | $51.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
ENVIRONMENTAL GRANTMAKERS ASSOCIATION20-8817646 | NEW YORK, NY | $51K | Cash | SUBAWARD - SPONSORED RESEARCH |
| TUSCALOOSA, AL | $50.3K | Cash | SUBAWARD - SPONSORED RESEARCH | |
ONE COW STANDING LLC11-3764955 | DURHAM, NC | $50.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
LODESTONE BIOMEDICAL LLC47-2187055 | LEBANON, NH | $50K | Cash | SUBAWARD - SPONSORED RESEARCH |
EAST END NRZ MARKET AND CAFE84-3527847 | BRIDGEPORT, CT | $50K | Cash | SUBAWARD - SPONSORED RESEARCH |
GREEN AND HEALTHY HOMES INITIATIVE INC52-1786577 | BALTIMORE, MD | $49.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
| FARMINGDALE, NY | $49.5K | Cash | SUBAWARD - SPONSORED RESEARCH | |
JUSTLEADERSHIPUSA INC90-1019268 | NEW YORK, NY | $48K | Cash | SUBAWARD - SPONSORED RESEARCH |
AMERICAN UNIVERSITY53-0196549 | WASHINGTON, DC | $47.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
SMART POWER INC | ARLINGTON, VA | $47.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
VILLANOVA UNIVERSITY23-1352688 | VILLANOVA, PA | $46.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
CLIFFORD BEERS COMMUNITY CARE CENER INC | NEW HAVEN, CT | $46.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
INOVA HEALTH CARE SERVICES54-0620889 | FAIRFAX, VA | $44.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
| LEXINGTON, KY | $43.9K | Cash | SUBAWARD - SPONSORED RESEARCH | |
AERODYNE RESEARCH INC | BILLERICA, MA | $43.7K | Cash | SEE PART IV |
CONNECTICUT HARM REDUCTION ALLIANCE47-4312705 | HARTFORD, CT | $43.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
MICROVIDE LLC26-4388720 | MILLS SPRING, NC | $43.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
CARNEGIE MELLON UNIVERSITY25-0969449 | PITTSBURGH, PA | $42.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
BAYLOR RESEARCH INSTITUTE75-1921898 | DALLAS, TX | $40.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
MRIGLOBAL44-0545878 | KANSAS CITY, MO | $40.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE NEMOURS FOUNDATION59-0634433 | JACKSONVILLE, FL | $40.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
RECOVERY NETWORK OF PROGRAMS INC | SHELTON, CT | $40K | Cash | SUBAWARD - SPONSORED RESEARCH |
ALLIANCE FOR LIVING INC | NEW LONDON, CT | $40K | Cash | SEE PART IV |
EDTOGETHER INC81-2550548 | BOSTON, MA | $39.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
ALLIANCE FOR COMMUNITY EMPOWERMENT INC | BRIDGEPORT, CT | $39.8K | Cash | SEE PART IV |
TRUSTEES OF DARTMOUTH COLLEGE | HANOVER, NH | $39.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
OREGON STATE UNIVERSITY61-1730890 | CORVALLIS, OR | $39.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
ESSENTIA INSTITUTE OF RURAL HEALTH27-1291124 | DULUTH, MN | $38.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
BARNARD COLLEGE13-1628149 | NEW YORK, NY | $37.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
FAIR HAVEN COMMUNITY HEALTH CLINIC INC | NEW HAVEN, CT | $37.5K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
ESSEX COUNTY OBGYN ASSOCIATES INC | DANVERS, MA | $37.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF CALIFORNIA RIVERSIDE95-6006142 | RIVERSIDE, CA | $37K | Cash | SUBAWARD - SPONSORED RESEARCH |
| TAMPA, FL | $36.7K | Cash | SUBAWARD - SPONSORED RESEARCH | |
NEW HYTES INC27-0772846 | NEW HAVEN, CT | $35K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
INSTITUTE FOR MEDICAL RESEARCH INC56-1655431 | DURHAM, NC | $34.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
| ATLANTA, GA | $33.9K | Cash | SUBAWARD - SPONSORED RESEARCH | |
SIEMENS MEDICAL SOLUTIONS USA INC22-2417778 | KNOXVILLE, TN | $31.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
RUSH UNIVERSITY MEDICAL CENTER36-2174823 | CHICAGO, IL | $30.2K | Cash | SUBAWARD - SPONSORED RESEARCH |
ULYSSES S GRANT FOUNDATION | NEW HAVEN, CT | $30K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
ECONOMETRIC SOCIETY INC32-0402835 | NEW HAVEN, CT | $30K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
| HOLYOKE, MA | $29.8K | Cash | SUBAWARD - SPONSORED RESEARCH | |
| RENO, NV | $29.5K | Cash | SUBAWARD - SPONSORED RESEARCH | |
NORTHEAST MEDICAL GROUP INC | STRATFORD, CT | $28.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
CITY OF NEW HAVEN | NEW HAVEN, CT | $28.8K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
ROCHESTER INSTITUTE OF TECHNOLOGY16-0743140 | ROCHESTER, NY | $27.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE HOSPITAL OF CENTRAL CONNECTICUT | NEW BRITAIN, CT | $26.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE UNIVERSITY OF SOUTH CAROLINA57-6001153 | COLUMBIA, SC | $26.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE HOWARD UNIVERSITY53-0204707 | WASHINGTON, DC | $26.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
CHABAD AT YALE UNIVERSITY INC45-2786550 | NEW HAVEN, CT | $26.2K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
| COLLEGE STATION, TX | $25.1K | Cash | SUBAWARD - SPONSORED RESEARCH | |
DALLAS VA RESEARCH CORPORATION75-2329831 | DALLAS, TX | $23.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
AURELIAN HONOR SOCIETY INCORPORATED | NEW HAVEN, CT | $22.9K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
EMMANUEL COLLEGE | BOSTON, MA | $22.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
PORTLAND STATE UNIVERSITY36-4776757 | PORTLAND, OR | $22.3K | Cash | SUBAWARD - SPONSORED RESEARCH |
MONTCLAIR STATE UNIVERSITY22-2912682 | MONTCLAIR, NJ | $21.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
SYRACUSE UNIVERSITY15-0532081 | SYRACUSE, NY | $21K | Cash | SUBAWARD - SPONSORED RESEARCH |
YALE NEW HAVEN HOSPITAL | NEW HAVEN, CT | $20K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
ENVIRONMENTAL LAW INSTITUTE52-0901863 | WASHINGTON, DC | $19.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE CHILDREN'S MERCY HOSPITAL44-0605373 | KANSAS CITY, MO | $18.6K | Cash | SUBAWARD - SPONSORED RESEARCH |
APNHA PLACE TO NOURISH YOUR HEALTH22-2506184 | NEW HAVEN, CT | $17.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
SOUTH DAKOTA STATE UNIVERSITY46-6000364 | BROOKINGS, SD | $17.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE LUTHERAN UNIVERSITY ASSOCIATION INC35-0868125 | VALPARAISO, IN | $17.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
INSTITUTE FOR COMMUNITY RESEARCH INC | HARTFORD, CT | $16.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
| NEW HAVEN, CT | $16.5K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT | |
THE GREATER NEW HAVEN CHAMBER OF COMMERCE INC | NEW HAVEN, CT | $15.5K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
NATIONAL CHILDREN'S ALLIANCE INC63-1044781 | WASHINGTON, DC | $15.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
FLAGLER COLLEGE INC59-1157081 | ST AUGUSTINE, FL | $15K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
METIS FOUNDATION47-2219464 | SAN ANTONIO, TX | $14.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
BEDFORD VA RESEARCH CORPORATION INC | BEDFORD, MA | $13.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
NORTH CAROLINA STATE UNIVERSITY56-6000756 | RALEIGH, NC | $13.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
THE MEDICAL COLLEGE OF WISCONSIN INC39-0806261 | MILWAUKEE, WI | $13.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
RANDOLPH-MACON COLLEGE54-0505940 | ASHLAND, VA | $13.4K | Cash | SUBAWARD - SPONSORED RESEARCH |
SEARCH TECHNOLOGY INC37-1091327 | NORCROSS, GA | $13K | Cash | SUBAWARD - SPONSORED RESEARCH |
ACADEMIC PEDIATRICS ASSOCIATION51-0202446 | MCLEAN, VA | $13K | Cash | SEE PART IV |
EMERGENCY NURSES ASSOCIATION31-1703819 | SCHAUMBURG, IL | $12.7K | Cash | SUBAWARD - SPONSORED RESEARCH |
AMICUS BRAIN INNOVATIONS INC83-2893933 | CHAPPAQUA, NY | $12.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
COMMUNITY HEALTH CENTER INC | MIDDLETOWN, CT | $12.1K | Cash | SUBAWARD - SPONSORED RESEARCH |
LOAVES AND FISHES NEW HAVEN INC83-3038362 | NEW HAVEN, CT | $12K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
NEW YORK MEDICAL COLLEGE13-1099420 | VALHALLA, NY | $12K | Cash | SUBAWARD - SPONSORED RESEARCH |
BAYSTATE MEDICAL CENTER INC | SPRINGFIELD, MA | $11.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
UNIVERSITY OF LA VERNE95-1644026 | LA VERNE, CA | $11.5K | Cash | SUBAWARD - SPONSORED RESEARCH |
NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE | NEW HAVEN, CT | $11.5K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
SAINT LUKE'S HOSPITAL OF KANSAS CITY44-0545297 | KANSAS CITY, MO | $10.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
WHOLESOME WAVE INC26-0352899 | BRIDGEPORT, CT | $10.9K | Cash | SUBAWARD - SPONSORED RESEARCH |
VIRGINIA COMMONWEALTH UNIVERSITY54-6001758 | RICHMOND, VA | $10.8K | Cash | SUBAWARD - SPONSORED RESEARCH |
ALLIANCE FOR MIDDLE EAST PEACE INC20-5879279 | WASHINGTON, DC | $10K | Cash | DAF DISTRIBUTION |
AMERICAN MUSEUM OF NATURAL HISTORY13-6162659 | NEW YORK, NY | $10K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
CITYARTS INC13-2766701 | NEW YORK, NY | $10K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
THE GOVERNOR'S PREVENTION PARTNERSHIP | WETHERSFIELD, CT | $10K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
CORNELL UNIVERSITY15-0532082 | ITHACA, NY | $10K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
NEW YORK UNIVERSITY13-5562308 | NEW YORK, NY | $10K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
AMERICAN ACADEMY OF PEDIATRICS36-2275597 | ITASCA, IL | $10K | Cash | SEE PART IV |
NEW HAVEN SYMPHONY ORCHESTRA INC | NEW HAVEN, CT | $10K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
NEW HAVEN FESTIVALS INC22-3149569 | NEW HAVEN, CT | $10K | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
SAINT FRANCIS HOSPITAL AND MEDICAL CENTER | HARTFORD, CT | $9,935 | Cash | SUBAWARD - SPONSORED RESEARCH |
CURE CMD26-2640975 | LAKEWOOD, CA | $9,628 | Cash | SUBAWARD - SPONSORED RESEARCH |
APPALACHIAN STATE UNIVERSITY56-1176030 | BOONE, NC | $9,294 | Cash | SUBAWARD - SPONSORED RESEARCH |
THE NATURE CONSERVANCY53-0242652 | ARLINGTON, VA | $8,973 | Cash | SUBAWARD - SPONSORED RESEARCH |
ROWAN UNIVERSITY22-2764819 | GLASSBORO, NJ | $8,781 | Cash | SUBAWARD - SPONSORED RESEARCH |
YALE INTERNATIONAL RELATIONS INC23-7403870 | NEW HAVEN, CT | $8,500 | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
CHILDREN'S HOSPITAL INC72-0467503 | NEW ORLEANS, LA | $7,666 | Cash | SUBAWARD - SPONSORED RESEARCH |
ARTE INC54-2138181 | NEW HAVEN, CT | $7,500 | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
BALDWIN WALLACE UNIVERSITY34-0714629 | BEREA, OH | $7,490 | Cash | SUBAWARD - SPONSORED RESEARCH |
APEX COMMUNITY CARE INC22-2951387 | DANBURY, CT | $7,145 | Cash | SUBAWARD - SPONSORED RESEARCH |
BAYER HEALTHCARE LLC | SAINT LOUIS, MO | $7,127 | Cash | SUBAWARD - SPONSORED RESEARCH |
SOUTHERN NEVADA HEALTH DISTRICT88-0151573 | LAS VEGAS, NV | $7,035 | Cash | SUBAWARD - SPONSORED RESEARCH |
CT CYCLING ADVANCEMENT PROGRAM INC46-1774656 | MIDDLETOWN, CT | $7,000 | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
CONNECTICUT UNITED FOR RESEARCH EXCELLENCE INC | GROTON, CT | $7,000 | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
ASSOCIATION FOR JEWISH STUDIES INC23-7078939 | NEW YORK, NY | $6,750 | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
CORNELL SCOTT-HILL HEALTH CORPORATION | NEW HAVEN, CT | $6,500 | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
THE AMERICAN PEDIATRIC SOCIETY INC16-6078165 | THE WOODLANDS, TX | $6,500 | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
PUERTO RICO DEPARTMENT OF HEALTH66-0437470 | SAN JUAN, PR | $6,174 | Cash | SUBAWARD - SPONSORED RESEARCH |
DOWNTOWN EVENING SOUP KITCHEN INC22-2985448 | NEW HAVEN, CT | $6,000 | Cash | CHARITABLE CONTRIBUTION AND COMMUNITY SUPPORT |
GEORGE FOX UNIVERSITY93-0386839 | NEWBERG, OR | $6,000 | Cash | SUBAWARD - SPONSORED RESEARCH |
| CHARLESTON, WV | $5,830 | Cash | SUBAWARD - SPONSORED RESEARCH | |
THE AMERICAN GERIATRICS SOCIETY13-1950856 | NEW YORK, NY | $5,797 | Cash | SUBAWARD - SPONSORED RESEARCH |
| AUGUSTA, GA | $5,341 | Cash | SUBAWARD - SPONSORED RESEARCH | |
| Total | $137.2M | |||
LA JOLLA, CA
$6.5M
NEW HAVEN, CT
$4.4M
MASSACHUSETTS GENERAL HOSPITAL
BOSTON, MA
$3.7M
$3.3M
PHILADELPHIA, PA
$3.2M
NASHVILLE, TN
$2.8M
DURHAM, NC
$2.8M
NEW YORK, NY
$2.4M
CHILDREN'S HOSPITAL CORPORATION
BOSTON, MA
$2.4M
$2.3M
UNIVERSITY OF MASSACHUSETTS
BOSTON, MA
$2.3M
ROCHESTER, MN
$2.2M
CINCINNATI, OH
$2M
BRIGHAM AND WOMEN'S HOSPITAL INC
BOSTON, MA
$2M
NEW HAVEN, CT
$2M
REDWOOD CITY, CA
$2M
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
CAMBRIDGE, MA
$1.9M
BALTIMORE, MD
$1.9M
ST LOUIS, MO
$1.7M
CHAPEL HILL, NC
$1.7M
BIRMINGHAM, AL
$1.7M
LOS ANGELES, CA
$1.7M
NEW YORK, NY
$1.6M
MCLEAN HOSPITAL CORPORATION
BOSTON, MA
$1.5M
SEATTLE, WA
$1.4M
PITTSBURGH, PA
$1.4M
ATLANTA, GA
$1.4M
$1.3M
BETH ISRAEL DEACONESS MEDICAL CENTER INC
BOSTON, MA
$1.3M
HARTFORD HOSPITAL
HARTFORD, CT
$1.3M
YALE NEW HAVEN HOSPITAL
NEW HAVEN, CT
$1.3M
NEW YORK, NY
$1.3M
IRVINE, CA
$1.2M
$1.2M
SAN FRANCISCO, CA
$1.2M
$1.1M
SAN FRANCISCO, CA
$1.1M
$1.1M
NEW YORK, NY
$1M
WESTBURY, NY
$972.9K
PHILADELPHIA, PA
$954.4K
EVANSTON, IL
$943.6K
LOS ANGELES, CA
$919.1K
NEW YORK, NY
$868.5K
CHARLESTON, SC
$859K
ITHACA, NY
$851.2K
GAINESVILLE, FL
$844.9K
WEST HAVEN, CT
$813.5K
MADISON, WI
$812K
CORAL GABLES, FL
$811.6K
NEW HAVEN, CT
$776.4K
WASHINGTON, DC
$749.1K
SEATTLE, WA
$735.9K
BOSTON MEDICAL CENTER CORPORATION
BOSTON, MA
$713K
MINNEAPOLIS, MN
$679.1K
CHICAGO, IL
$677.9K
SAN FRANCISCO, CA
$671.6K
UNIVERSITY OF CONNECTICUT
STORRS, CT
$651.5K
LOS ANGELES, CA
$638.5K
FARMINGTON, CT
$637.4K
KANSAS CITY, MO
$612K
ALBUQUERQUE, NM
$608.9K
SALT LAKE CITY, UT
$590.8K
VIRGINIA BEACH, VA
$579.7K
MINNEAPOLIS, MN
$577.9K
CONTINUUM OF CARE INC
NEW HAVEN, CT
$568.6K
PHILADELPHIA, PA
$550.1K
BROWN UNIVERSITY
PROVIDENCE, RI
$543.2K
FORT WORTH, TX
$529.2K
BRONX, NY
$526K
ANN ARBOR, MI
$522.8K
PISCATAWAY, NJ
$515.7K
THE JACKSON LABORATORY
BAR HARBOR, ME
$501K
HOUSTON, TX
$500K
OKLAHOMA CITY, OK
$495.8K
AUSTIN, TX
$493.9K
NEW YORK, NY
$492.5K
MORGANTOWN, WV
$485.7K
MENANDS, NY
$481.6K
LOS ANGELES, CA
$468.4K
GRAND RAPIDS, MI
$468.1K
GRIFFIN HOSPITAL
DERBY, CT
$467.3K
COLUMBUS, OH
$465.9K
MEMPHIS, TN
$449.8K
TRUSTEES OF BOSTON UNIVERSITY
BOSTON, MA
$448.7K
OAKLAND, CA
$446.5K
LATHAM BIOPHARM GROUP INC
ELKRIDGE, MD
$434.1K
STATE COLLEGE, PA
$424.1K
HOUSTON, TX
$423.6K
MAINEHEALTH
PORTLAND, ME
$415.5K
JOSEPH SLIFKA CENTER FOR JEWISH LIFE AT YALE
NEW HAVEN, CT
$404.5K
COLLEGE PARK, MD
$404.1K
CHARLOTTESVILLE, VA
$402.5K
PHILADELPHIA, PA
$391.3K
NASHVILLE, TN
$386.7K
$375.1K
DANA-FARBER CANCER INSTITUTE INC
BOSTON, MA
$368.4K
LA JOLLA, CA
$366.1K
DAVIS, CA
$359.4K
SANTA BARBARA, CA
$359.3K
$349.4K
SAN JUAN, PR
$345K
STATE OF CONNECTICUT
HARTFORD, CT
$340.3K
ROCHESTER, NY
$335.1K
WASHINGTON, DC
$318.2K
THE UNIVERSITY OF RHODE ISLAND
KINGSTON, RI
$314.1K
$307.2K
BERKELEY, CA
$306.1K
EAST LANSING, MI
$305.2K
CLEVELAND, OH
$300.7K
BRIDGES HEALTHCARE INC
MILFORD, CT
$299K
GREENVILLE, SC
$298.9K
NORTHEASTERN UNIVERSITY
BOSTON, MA
$295.8K
SAN JUAN, PR
$291.4K
CAMDEN, NJ
$290.9K
WASHINGTON, DC
$282.5K
BLOOMINGTON, IN
$279.7K
KANSAS CITY, KS
$270.8K
CAMBRIDGE, MA
$266.1K
SEATTLE, WA
$265.1K
DENVER, CO
$257.2K
SANTA CLARA, CA
$254.4K
NEEDHAM, MA
$254.1K
NEW YORK, NY
$250.8K
NEW HAVEN, CT
$250K
EUGENE, OR
$250K
OMAHA, NE
$248.4K
LOS ANGELES, CA
$246.5K
LA JOLLA, CA
$241.3K
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
CAMBRIDGE, MA
$240.2K
ASHBURN, VA
$238K
NEW HAVEN INTERNATIONAL FESTIVAL OF ARTS AND IDEAS INC
NEW HAVEN, CT
$237.5K
SAN FRANCISCO, CA
$232.6K
TAMPA, FL
$231.4K
MENANDS, NY
$228K
DETROIT, MI
$217.7K
PASADENA, CA
$215.5K
OAKLAND, CA
$215.3K
THE JOHN B PIERCE LABORATORY INC
NEW HAVEN, CT
$215.3K
URBAN COMMUNITY ALLIANCE INC
NEW HAVEN, CT
$212.8K
MARKET NEW HAVEN INC
NEW HAVEN, CT
$206.3K
SAN JUAN, PR
$202.4K
HUNTINGTON, WV
$193.4K
TUCSON, AZ
$188.5K
OKLAHOMA CITY, OK
$183.6K
TEMPE, AZ
$181.2K
CLEVELAND, OH
$177.5K
INNOVATIONS FOR POVERTY ACTION
WASHINGTON, DC
$166.5K
LIBERATION PROGRAMS INC
BRIDGEPORT, CT
$164.5K
URBAN LEAGUE OF SOUTHERN CT INC
NEW HAVEN, CT
$164.5K
OAK RIDGE, TN
$162.1K
MIAMI, FL
$161K
WEST LAFAYETTE, IN
$159.9K
NEW HAVEN, CT
$159.4K
ST THOMAS, VI
$159.2K
NEW HAVEN, CT
$158.8K
LA JOLLA, CA
$155.4K
$154.4K
NEW HAVEN, CT
$153.7K
UNITED WAY OF GREATER NEW HAVEN INC
NEW HAVEN, CT
$152.5K
WEST CHESTER, PA
$152.3K
TAMPA, FL
$148.5K
BALTIMORE, MD
$147.6K
PRINCETON, NJ
$146.4K
LITTLE ROCK, AR
$143.8K
SAN FRANCISCO, CA
$139K
FALLS CHURCH, VA
$137.3K
FAIR HAVEN COMMUNITY HEALTH CLINIC INC
NEW HAVEN, CT
$135.1K
$135.1K
PORTLAND, OR
$134.5K
WHITE RIVER JUNCTION, VT
$132.1K
WASHINGTON, DC
$129.8K
BLACKSBURG, VA
$125.5K
GAITHERSBURG, MD
$124.9K
$124K
SAN DIEGO, CA
$122.5K
STANLEY STREET TREATMENT & RESOURCES INC
FALL RIVER, MA
$117.7K
NEW YORK, NY
$117.3K
$114.2K
LOS ALAMOS, NM
$112.6K
YALE LAW SCHOOL LEARNING CENTER INC
NEW HAVEN, CT
$110K
FAIRFAX, VA
$108.6K
DALLAS, TX
$100.3K
ROYAL OAK, MI
$100.2K
PALO ALTO, CA
$100K
NEW HAVEN, CT
$100K
NEW YORK, NY
$100K
PHILADELPHIA, PA
$92.2K
ST CROIX, VI
$88.3K
RESEARCH TRIANGLE PARK, NC
$87.9K
DETROIT, MI
$86.9K
$84.8K
THE WREXHAM FOUNDATION INC
NEW HAVEN, CT
$83.7K
LITTLE ROCK, AR
$81.8K
NEW YORK, NY
$81.6K
WINTER PARK, FL
$81.3K
ORLANDO, FL
$80.2K
NEW HAVEN, CT
$80K
YALE UNIVERSITY DRAMATIC ASSOCIATION INC
NEW HAVEN, CT
$80K
TROY, NY
$79.9K
NEWARK, DE
$79.1K
NEW HAVEN, CT
$79K
NEEDHAM, MA
$78.8K
$78.7K
ENGLEWOOD, CO
$78.4K
TUFTS UNIVERSITY
MEDFORD, MA
$77.1K
PHILADELPHIA, PA
$75K
HOUSTON, TX
$71.1K
ATLANTA, GA
$71K
IOWA CITY, IA
$69.9K
BATON ROUGE, LA
$67.8K
$66.1K
L2 DIAGNOSTICS LLC
WOODBRIDGE, CT
$64.7K
CINCINNATI, OH
$64.4K
LEBANON, NH
$63K
RHODE ISLAND HOSPITAL
PROVIDENCE, RI
$61.5K
THE MIRIAM HOSPITAL
PROVIDENCE, RI
$60.7K
$60.2K
NEW YORK, NY
$59.8K
HARVARD PILGRIM HEALTH CARE INC
CANTON, MA
$59.8K
NOTRE DAME, IN
$58.7K
IQVIA INC
PARSIPPANY, NJ
$57K
$53.6K
FORT COLLINS, CO
$53.5K
RICHMOND, VA
$51.5K
NEW HAVEN, CT
$51.4K
GREENVILLE, NC
$51.2K
NEW YORK, NY
$51K
TUSCALOOSA, AL
$50.3K
DURHAM, NC
$50.1K
LEBANON, NH
$50K
BRIDGEPORT, CT
$50K
BALTIMORE, MD
$49.9K
FARMINGDALE, NY
$49.5K
NEW YORK, NY
$48K
WASHINGTON, DC
$47.6K
SMART POWER INC
ARLINGTON, VA
$47.5K
VILLANOVA, PA
$46.8K
CLIFFORD BEERS COMMUNITY CARE CENER INC
NEW HAVEN, CT
$46.5K
FAIRFAX, VA
$44.6K
LEXINGTON, KY
$43.9K
AERODYNE RESEARCH INC
BILLERICA, MA
$43.7K
HARTFORD, CT
$43.7K
MILLS SPRING, NC
$43.5K
PITTSBURGH, PA
$42.9K
DALLAS, TX
$40.9K
KANSAS CITY, MO
$40.6K
JACKSONVILLE, FL
$40.3K
RECOVERY NETWORK OF PROGRAMS INC
SHELTON, CT
$40K
ALLIANCE FOR LIVING INC
NEW LONDON, CT
$40K
BOSTON, MA
$39.9K
ALLIANCE FOR COMMUNITY EMPOWERMENT INC
BRIDGEPORT, CT
$39.8K
TRUSTEES OF DARTMOUTH COLLEGE
HANOVER, NH
$39.8K
CORVALLIS, OR
$39.2K
DULUTH, MN
$38.1K
NEW YORK, NY
$37.7K
FAIR HAVEN COMMUNITY HEALTH CLINIC INC
NEW HAVEN, CT
$37.5K
ESSEX COUNTY OBGYN ASSOCIATES INC
DANVERS, MA
$37.5K
RIVERSIDE, CA
$37K
NEW HAVEN, CT
$35K
DURHAM, NC
$34.8K
$33.9K
KNOXVILLE, TN
$31.7K
CHICAGO, IL
$30.2K
ULYSSES S GRANT FOUNDATION
NEW HAVEN, CT
$30K
NEW HAVEN, CT
$30K
$29.8K
$29.5K
NORTHEAST MEDICAL GROUP INC
STRATFORD, CT
$28.8K
CITY OF NEW HAVEN
NEW HAVEN, CT
$28.8K
ROCHESTER, NY
$27.9K
THE HOSPITAL OF CENTRAL CONNECTICUT
NEW BRITAIN, CT
$26.6K
COLUMBIA, SC
$26.3K
WASHINGTON, DC
$26.3K
NEW HAVEN, CT
$26.2K
COLLEGE STATION, TX
$25.1K
DALLAS, TX
$23.7K
AURELIAN HONOR SOCIETY INCORPORATED
NEW HAVEN, CT
$22.9K
EMMANUEL COLLEGE
BOSTON, MA
$22.3K
PORTLAND, OR
$22.3K
MONTCLAIR, NJ
$21.7K
SYRACUSE, NY
$21K
YALE NEW HAVEN HOSPITAL
NEW HAVEN, CT
$20K
WASHINGTON, DC
$19.1K
KANSAS CITY, MO
$18.6K
NEW HAVEN, CT
$17.9K
BROOKINGS, SD
$17.7K
VALPARAISO, IN
$17.4K
INSTITUTE FOR COMMUNITY RESEARCH INC
HARTFORD, CT
$16.8K
$16.5K
THE GREATER NEW HAVEN CHAMBER OF COMMERCE INC
NEW HAVEN, CT
$15.5K
WASHINGTON, DC
$15.1K
ST AUGUSTINE, FL
$15K
SAN ANTONIO, TX
$14.9K
BEDFORD VA RESEARCH CORPORATION INC
BEDFORD, MA
$13.8K
RALEIGH, NC
$13.7K
MILWAUKEE, WI
$13.7K
ASHLAND, VA
$13.4K
NORCROSS, GA
$13K
MCLEAN, VA
$13K
SCHAUMBURG, IL
$12.7K
CHAPPAQUA, NY
$12.5K
COMMUNITY HEALTH CENTER INC
MIDDLETOWN, CT
$12.1K
NEW HAVEN, CT
$12K
VALHALLA, NY
$12K
BAYSTATE MEDICAL CENTER INC
SPRINGFIELD, MA
$11.8K
LA VERNE, CA
$11.5K
NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE
NEW HAVEN, CT
$11.5K
KANSAS CITY, MO
$10.9K
BRIDGEPORT, CT
$10.9K
RICHMOND, VA
$10.8K
WASHINGTON, DC
$10K
NEW YORK, NY
$10K
NEW YORK, NY
$10K
THE GOVERNOR'S PREVENTION PARTNERSHIP
WETHERSFIELD, CT
$10K
ITHACA, NY
$10K
NEW YORK, NY
$10K
ITASCA, IL
$10K
NEW HAVEN SYMPHONY ORCHESTRA INC
NEW HAVEN, CT
$10K
NEW HAVEN, CT
$10K
SAINT FRANCIS HOSPITAL AND MEDICAL CENTER
HARTFORD, CT
$9,935
LAKEWOOD, CA
$9,628
BOONE, NC
$9,294
ARLINGTON, VA
$8,973
GLASSBORO, NJ
$8,781
NEW HAVEN, CT
$8,500
NEW ORLEANS, LA
$7,666
NEW HAVEN, CT
$7,500
BEREA, OH
$7,490
DANBURY, CT
$7,145
BAYER HEALTHCARE LLC
SAINT LOUIS, MO
$7,127
LAS VEGAS, NV
$7,035
MIDDLETOWN, CT
$7,000
CONNECTICUT UNITED FOR RESEARCH EXCELLENCE INC
GROTON, CT
$7,000
NEW YORK, NY
$6,750
CORNELL SCOTT-HILL HEALTH CORPORATION
NEW HAVEN, CT
$6,500
THE WOODLANDS, TX
$6,500
SAN JUAN, PR
$6,174
NEW HAVEN, CT
$6,000
NEWBERG, OR
$6,000
CHARLESTON, WV
$5,830
NEW YORK, NY
$5,797
AUGUSTA, GA
$5,341
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$117.2M
VA/DoD Award Count
10
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding (partial)
$3B
Awards Found
200+
Additional awards may exist. View all on USAspending.gov →
Department of Health and Human Services
$126.6M
THE NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
Department of Health and Human Services
$102.9M
YALE CLINICAL AND TRANSLATIONAL SCIENCE AWARD
Department of Health and Human Services
$78.3M
PRONET: PSYCHOSIS-RISK OUTCOMES NETWORK
Department of Health and Human Services
$67.5M
THE AUTISM BIOMARKERS CONSORTIUM FOR CLINICAL TRIALS
Department of Health and Human Services
$64.6M
YALE COMPREHENSIVE CANCER CENTER
Department of Health and Human Services
$57.5M
INSULIN RESISTANCE INTERVENTION AFTER STROKE TRIAL
Department of Health and Human Services
$48.7M
PROCAN: PSYCHOSIS RISK OUTCOMES COMPOUND ASSESSMENT NETWORK - PROJECT SUMMARY IT HAS NOW BEEN TWO DECADES SINCE THE CLINICAL HIGH RISK FOR PSYCHOSIS (CHR) CRITERIA WERE FIRST FORMULATED IN SERVICE OF THE GOAL OF PREVENTING PSYCHOTIC DISORDERS, ONE OF THE MOST URGENT UNMET CLINICAL NEEDS IN BEHAVIORAL HEALTH IF NOT IN ALL OF MEDICINE. AS WITH MOST PSYCHIATRIC PATIENTS, CHR PATIENTS BENEFIT FROM PSYCHOTHERAPIES BUT ARE ALSO OFTEN LEFT WITH IMPORTANT TREATMENT NEEDS NOT FULLY ADDRESSED. DESPITE THE CRITICAL PUBLIC HEALTH NEED, DRUG DEVELOPMENT FOR CHR IS VIEWED IN MANY QUARTERS AS RISKY. THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH AND THE NATIONAL INSTITUTE OF MENTAL HEALTH ALONG WITH OTHER PUBLIC AND PRIVATE PARTNERS ESTABLISHED THE PSYCHOSIS RISK OUTCOMES NETWORK (PRONET) AND THE ACCELERATING MEDICINES PARTNERSHIP® SCHIZOPHRENIA OBSERVATIONAL STUDY (AMP® SCZ) IN 2020 TO DEVELOP TOOLS TO PARSE THE HETEROGENEITY OF THE CHR SYNDROME AND DE-RISK THE DRUG DEVELOPMENT THAT COULD LEAD TO IMPROVEMENT OF SYMPTOMS AND FUNCTIONING IN CHR PATIENTS AND ULTIMATELY TO THE PREVENTION OF SCHIZOPHRENIA. THE CURRENT PROJECT, THE PSYCHOSIS RISK OUTCOMES COMPOUND ASSESSMENT NETWORK (PROCAN), FOLLOWS UP ON THIS SUCCESSFUL PREVIOUS INITIATIVE AND WILL ESTABLISH INFRASTRUCTURE TO DETERMINE, IN PARTNERSHIP WITH THE CLINICAL TRIALS DATA PROCESSING ANALYSIS AND COORDINATION CENTER (CT-DPACC), WHETHER THE BIOLOGICAL, DIGITAL, COGNITIVE, AND CLINICAL OUTCOME MEASURES DEVELOPED IN AMP SCZ ARE VIABLE AS DRUG DEVELOPMENT TOOLS (DDTS) FOR USE IN PHASE 2 CLINICAL TRIALS IN PARTICIPANTS AT CLINICAL HIGH RISK FOR PSYCHOSIS (CHR). ONE OR TWO PHASE 2-READY COMPOUNDS WILL BE STUDIED, EACH SELECTED BY THE AMP SCZ COMPOUND SELECTION COMMITTEE. AIM 1 WILL EVALUATE THE POTENTIAL OF SELECTED COMPOUND(S) TO DETECT A SIGNAL IN CHR PARTICIPANTS ON ONE OR MORE BIOLOGICAL, DIGITAL, COGNITIVE, OR CLINICAL OUTCOME MEASURES DEVELOPED IN THE AMP SCZ OBSERVATIONAL STUDY WITHIN A 16 WEEK TIME FRAME. WE PROPOSE TWO TRIALS, EACH WITH 15 SITES, EACH WITH THREE ARMS AND 65 PARTICIPANTS PER ARM (TOTAL PER TRIAL N=195), AND EACH WITH THE NETWORK RFA SPECIFIED MAXIMUM 16 WEEK FOLLOW-UP. COMPOUND SAFETY WILL ALSO BE EVALUATED. AIM 2 WILL DETERMINE WHETHER BIOMARKERS DEVELOPED IN THE AMP SCZ OBSERVATIONAL STUDY AND/OR NOVEL BIOMARKERS CAN ACT AS PHARMACODYNAMIC READOUTS OF DRUG RESPONSE AND/OR PROVIDE INSIGHTS INTO PROPOSED MECHANISMS OR PATHWAYS UNDERLYING CHR FOR PSYCHOSIS. WE PROPOSE BIOMARKER TIMEPOINTS AT BASELINE AND 8 AND 16 WEEKS. IF OUTCOME OR BIOMARKER SIGNALS ARE DETECTED, FINDINGS WILL PAVE THE WAY FOR FURTHER DEVELOPMENT OF PHASE-SPECIFIC AND SAFE NEW INTERVENTIONS TO BENEFIT CHR PATIENTS AND THEIR FAMILIES AND COMMUNITIES.
Department of Health and Human Services
$47.9M
DEFINING SIGNATURES FOR IMMUNE RESPONSIVENESS BY FUNCTIONAL SYSTEMS IMMUNOLOGY
Department of Health and Human Services
$39.6M
COSTIMULATORY MECHANISM OF AUTOIMMUNITY
Department of Health and Human Services
$38.5M
CLINICAL AND TRANSLATIONAL SCIENCE AWARD
Department of Health and Human Services
$37.9M
DATA COORDINATION CENTER FOR THE RMN
Department of Health and Human Services
$35.9M
CENTER FOR INTERDISCIPLINARY RESEARCH ON AIDS
Department of Health and Human Services
$35.9M
YALE SPORE IN SKIN CANCER
Department of Health and Human Services
$35.4M
YALE-MAYO FDA CENTER FOR EXCELLENCE IN REGULATORY SCIENCE AND INNOVATION
Department of Health and Human Services
$33.8M
YALE CENTER FOR THE STUDY OF TOBACCO PRODUCT USE AND ADDICTION: FLAVORS, NICOTINE AND OTHER CONSTITUENTS (YCSTP)
Department of Health and Human Services
$31.5M
YALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAM
Department of Health and Human Services
$31M
DIABETES ENDOCRINOLOGY RESEARCH CENTER
Department of Health and Human Services
$29.2M
YALE/NIDA NEUROPROTEOMICS RESEARCH CENTER
Department of Health and Human Services
$28.8M
CTR FOR TRANSLATIONAL NEUROSCIENCE OF ALCOHOL
National Science Foundation
$28.7M
GRADUATE RESEARCH FELLOWSHIP PROGRAM
National Science Foundation
$27.7M
GRADUATE RESEARCH FELLOWSHIP PROGRAM (GRFP)
Department of Health and Human Services
$27.1M
MEDICAL SCIENTIST TRAINING PROGRAM
Department of Health and Human Services
$26.7M
CLAUDE D PEPPER OLDER AMERICANS INDEPENDENCE CENTER AT YALE
Department of Health and Human Services
$26.5M
A NON-VIRAL CRISPR-MEDIATED GENOME EDITING DELIVERY PLATFORM AS A POTENTIAL THERAPY FOR NEUROGENETIC DISEASES - GENOME EDITING HOLDS GREAT PROMISE FOR THE TREATMENT OF MANY GENETIC DISEASES; HOWEVER ITS APPLICATION IN THE CLINIC HAS BEEN SLOW DUE TO THE LACK OF THE SAFE DELIVERY TOOLS AND SIGNIFICANT COST AND TIME INVESTMENT REQUIRED TO CUSTOM-DEVELOP INDIVIDUAL THERAPIES. IN OUR SCGE PROGRAM PHASE 1 STUDY, WE DEVELOPED A CHEMICALLY MODIFIED RIBONUCLEOPROTEIN (CRNP)-BASED GENE DELIVERY SYSTEM THAT SPECIFICALLY TARGETS NEURONAL CELLS THROUGHOUT THE BRAIN AFTER INTRATHECAL (IT) ADMINISTRATION. THE OVERARCHING GOAL OF THIS APPLICATION IS TO APPLY THIS NOVEL GENE EDITING TECHNOLOGY TOWARDS THE TREATMENT OF TWO SEVERE NEURODEVELOPMENTAL DISORDERS (NDD): ANGELMAN SYNDROME (AS) AND H1-4 SYNDROME (HIST1H1E SYNDROME). AS IS A DEVASTATING NEURODEVELOPMENTAL DISEASE CAUSED BY THE DEFICIENCY OF THE MATERNAL AND BRAIN SPECIFIC IMPRINTING UBE3A GENE IN HUMAN CHROMOSOME 15Q11-Q13 REGION. THE STRUCTURE OF UBE3A IS INTACT IN THE PATERNAL CHROMOSOME IN ALL AS CASES BUT TRANSCRIPTIONALLY REPRESSED BY A NON-CODING AND ANTISENSE RNA OF UBE3A (UBE3A-ATS) MEDIATED MECHANISM. IT HAS BEEN SHOWN CONVINCINGLY THAT REDUCTION OF UBE3A-ATS BY ANTISENSE OLIGO (ASO), TOPOISOMERASE INHIBITORS, AND VIRUS DELIVERED CAS9 GENE EDITING CAN DE-REPRESS THE EXPRESSION OF UBE3A AND CORRECT THE ABNORMAL NEUROLOGICAL PHENOTYPES IN AS MOUSE MODELS. H1-4 SYNDROME IS CAUSED BY A GAIN OF FUNCTION MECHANISM DUE TO A MUTATED PROTEIN WITH ABERRANT C-TERMINAL FRAMESHIFT TAIL (CFT). H1-4 SYNDROME HAS SIMILAR BUT MILDER CLINICAL FEATURES THAN AS. THERE IS NO EFFECTIVE INTERVENTION FOR H1-4 SYNDROME. THUS, A LONG- TERM MOLECULAR THERAPY FOR AS AND H1-4, AS WELL AS OTHER NDDS IS URGENTLY NEEDED. IN OUR PRECLINICAL STUDY USING A WELL VALIDATED AS MOUSE MODEL, WE DEMONSTRATED THAT A SINGLE IT DELIVERY OF UBE3A ANTISENSE-TARGETING RNP/CAS9EFFICIENTLY DE-REPRESSES THE EXPRESSION OF UBE3A FROM THE PATERNAL CHROMOSOME, LEADING TO CORRECTION OF NEUROBEHAVIORAL PHENOTYPES. SIMILARLY, THE KNOCKDOWN OF H1-4 CFT RESCUE THE ABNORMAL PHENOTYPES IN H1- 4 HUMANIZED MICE. WE PROPOSE OUR CRNP-BASED PLATFORM FOR THE TREATMENT OF AS AND H1-4 SYNDROME UTILIZING THE SAME GENOME EDITOR (CRISPR), DELIVERY SYSTEM (CRNPS), ROUTE (IT), TARGET CELL TYPE (NEURONS), THERAPEUTIC MECHANISM (GENETIC INACTIVATION) AND OVERALL TRIAL DESIGN. WE HAVE ASSEMBLED AN OUTSTANDING TEAM FROM YALE AND RUSH UNIVERSITY WITH STRONG AND COMPLEMENTARY EXPERTISE IN THE AREAS OF PRECLINICAL, IND ENABLING STUDIES, AND CLINICAL TRIALS. THE SUCCESS OF THIS STUDY WILL LEAD TO THE FIRST EVER GENE EDITING BASED THERAPY FOR AS AND H1- 4. MORE IMPORTANTLY, IT WILL SUPPORT A PARADIGM SHIFT FOR GENOME EDITING; RAPIDLY EXPANDING THE NUMBER OF NEUROGENETIC DISEASES TREATED BY IN VIVO GENE EDITING AND ACCELERATING THE TRANSITION OF GENOME EDITING TECHNOLOGY INTO CLINICAL APPLICATIONS.
Department of Health and Human Services
$25.8M
PSYCHOTHERAPY DEVELOPMENT RESEARCH CENTER
Department of Health and Human Services
$25.5M
YALE ALZHEIMER DISEASE RESEARCH CENTER
Department of Health and Human Services
$25.2M
YALE SPORE IN LUNG CANCER (YSILC): THE BIOLOGY AND PERSONALIZED TREATMENT OF LUNG CANCER
Department of Health and Human Services
$23.2M
IMPACT OF FGF21 ON HEALTHSPAN AND LIFESPAN
Department of Health and Human Services
$23.2M
RADX-RAD DISCOVERIES & DATA: CONSORTIUM COORDINATION CENTER PROGRAM ORGANIZATION - ABSTRACT PREPARING SARS-COV-2 TESTING DATA FOR REUSE REQUIRES MAKING THE DATA SYNTACTICALLY AND SEMANTICALLY EQUIVALENT. STANDARDIZATION OF TERMINOLOGIES AND A COMMON DATA MODEL ACCOMPLISH THE FORMER, WHILE THE LATTER IS ACCOMPLISHED THROUGH UNDERSTANDING THE DATA AND MAKING IT COMPARABLE ACROSS RADX-RAD AWARDEES BY BENCHMARKING AGAINST KNOWN GOLD STANDARDS. THE STANDARDIZATION OF SAMPLES IS AS IMPORTANT AS STANDARDIZING THE DATA, PARTICULARLY IN THE HIGHLY INNOVATIVE RADX-RAD PROGRAM, WHERE NEW TECHNOLOGIES WILL BE DEVELOPED OR OPTIMIZED FOR DEPLOYMENT IN VARIOUS SETTINGS. HIGHLY MOTIVATED RADX-RAD AWARDEES WILL RECEIVE ADVICE ON HOW THEIR DIAGNOSTICS COMPARE TO FDA-APPROVED ONES, WITH EACH OTHER, HOW THEIR DIAGNOSTIC PERFORMS IN INDEPENDENT TESTING, AS WELL AS HOW TO ENSURE THE TESTS ARE USABLE IN REAL WORLD SETTINGS. IN COLLABORATION WITH UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, UNIVERSITY OF CALIFORNIA SAN DIEGO RESEARCHERS IN INFORMATICS/DATA SCIENCE AND INFECTIOUS DISEASES WITH AMPLE EXPERIENCE IN LEADING LARGE CONSORTIA HAVE DESIGNED A UNIQUE RADX- RAD CONSORTIUM DATA AND COORDINATION CENTER (RADCDCC). THIS CENTER IS BASED ON THREE PILLARS: (1) EFFECTIVE ADMINISTRATION AND COORDINATION AMONG AWARDEES, NIH, AND OTHER PROGRAMS;; (2) INNOVATIVE APPROACHES AND TOOLS TO COLLECT AND STANDARDIZE DATA AND METADATA TO PROMOTE FINDABILITY, ACCESSIBILITY, INTEROPERABILITY AND REUSE (FAIR) FOR DATA SHARING;; AND (3) PRINCIPLED PREPARATION OF STANDARDIZED SAMPLES WITH KNOWN QUANTITIES OF VIRAL LOADS, AND STANDARDIZED PROCEDURES FOR TESTING NEW DIAGNOSTICS TO ALLOW COMPARISON ACROSS TESTS AND CALIBRATION OF NEW TECHNOLOGIES. BACKED BY SOPHISTICATED HIPAA-COMPLIANT CLOUD SERVICES, USER FRIENDLY WEB-TOOLS, AND EXTENSIVE SUPPORT FROM UCSD’S FACILITIES FOR COMPUTATION AND FOR CLINICAL RESEARCH, THE RADCDCC WILL INTERFACE WITH OTHER RADX PROGRAMS AND OTHER COVID-19 FOCUSED PROGRAMS AT NIH TO ENSURE ALIGNMENT OF AWARDEES, NIH AND THE PUBLIC IN THE PURSUIT OF EFFECTIVE, AFFORDABLE, AND DEPLOYABLE NEW TECHNOLOGIES FOR TESTING.
National Science Foundation
$21.1M
GRADUATE RESEARCH FELLOWSHIP PROGRAM (GRFP)
Department of Health and Human Services
$21.1M
SILVIO O.CONTE DIGESTIVE DISEASES RESEARCH CORE CENTERS
Department of Health and Human Services
$20.6M
IMPACT-MH: CLINICAL AND BEHAVIORAL FINGERPRINTS OF PSYCHOPATHOLOGY - SUMMARY PSYCHIATRIC SYMPTOMS ARE A LEADING CAUSE OF SUFFERING AND DISABILITY WORLDWIDE. DECADES OF RESEARCH HAVE FOCUSED ON UNDERSTANDING THEIR ETIOLOGY AND UNDERPINNINGS, TYPICALLY USING A DIAGNOSIS-BASED APPROACH IN WHICH INDIVIDUALS WITH A GIVEN CONDITION ARE COMPARED TO A MATCHED ‘CONTROL’ GROUP. LESS WORK HAS FOCUSED ON CHARACTERIZING THE LONGITUDINAL COURSE OF SYMPTOMS AT THE INDIVIDUAL LEVEL IN RELATION TO UNDERLYING COGNITIVE, AFFECTIVE, AND BEHAVIORAL MECHANISMS. RECOGNIZING THAT MOST (IF NOT ALL) PSYCHIATRIC DISORDERS ARE DEFINED BY THEIR LONGITUDINAL COURSE, THIS APPLICATION MOVES BEYOND THE LIMITATIONS OF TRADITIONAL DIAGNOSIS-CENTERED AND ‘CASE-CONTROL’ DESIGNS TO COLLECT LONGITUDINAL DATA OVER TWO YEARS FROM A LARGE SAMPLE (N=2400), HIGHLY ENRICHED FOR PSYCHOPATHOLOGY ACROSS A WIDE RANGE OF TRADITIONAL DIAGNOSES, TO IDENTIFY PREDICTIVE MARKERS OF SYMPTOM CHANGE USING ASSESSMENTS THAT CAN BE EASILY IMPLEMENTED IN REAL-WORLD SETTINGS. SPECIFICALLY, WE WILL COLLECT: (I) DATA EMBEDDED IN ELECTRONIC HEALTH RECORDS (EHR), INCLUDING SOCIAL DETERMINANTS OF HEALTH; (II) TRADITIONAL CLINICAL MEASURES TYPICALLY USED IN DIAGNOSIS-BASED APPROACHES (E.G., CLINICAL INTERVIEWS, WELL- VALIDATED CLINICAL SCALES); (III) RECENTLY DEVELOPED COMPUTATIONAL BEHAVIORAL TASKS WITH DEMONSTRATED SENSITIVITY TO LATENT CONSTRUCTS AND TO WITHIN-PERSON CHANGE; (IV) SHORT GAMIFIED BEHAVIORAL MEASURES OF MOOD AND REWARD-RELEVANT CONSTRUCTS, MEASURED REPEATEDLY; (V) SPOKEN NARRATIVE RESPONSES TO UNIFORM PROMPTS FOR NATURAL LANGUAGE PROCESSING (NLP) ANALYSES; AND (VI) PATIENT-DERIVED AND NIH TOOLBOX CONTINUOUS MEASURES OF KEY TRANSDIAGNOSTIC OUTCOMES. THESE DATA WILL BE ANALYZED USING ADVANCED STATISTICAL AND MACHINE LEARNING APPROACHES (E.G., LATENT GROWTH CURVE MODELING, NEURAL NETWORK TRANSFORMER MODELING), CONSISTENT WITH THE RECOMMENDATIONS SET FORTH IN THE IMPACT-MH RFA. IN AIM 1, WE WILL USE THIS RICH DATASET TO TEST THE PREDICTIVE VALUE OF ‘TRADITIONAL’ (EHR, OTHER CLINICAL) VS COMPUTATIONAL AND NLP DATA IN PREDICTING OUTCOMES. WE WILL FURTHER TEST THE DIFFERENTIAL PREDICTIVE VALUE OF COMBINATIONS OF MEASURES, INCLUDING SPARSE AND DENSE BEHAVIORAL SAMPLING, SEEKING TO IDENTIFY A MINIMUM SET OF MEASURES WITH MAXIMUM ADDED CLINICAL VALUE. IN AIM 2, WE WILL EXAMINE LONGITUDINAL CLINICAL TRAJECTORIES USING DATA-DRIVEN TRAJECTORY ANALYSIS OF MULTIDIMENSIONAL CLINICAL AND COMPUTATIONAL FINGERPRINTS; THIS APPROACH MAY ULTIMATELY BE USED TO GENERATE NORMATIVE MODELS TO TRACK AND FORECAST CLINICAL COURSE IN PATIENTS. FINALLY, IN AIM 3, WE WILL SEEK TO IDENTIFY SUBGROUPS, BASED ON COMPUTATIONAL FINGERPRINT SIMILARITIES AT BASELINE, THAT PREDICT DIFFERENCES IN OUTCOMES AT 2-YEAR FOLLOW-UP, AND TO TEST WHETHER OPTIMAL PREDICTIVE MODELS DIFFER AMONG SUCH SUBGROUPS. THIS RICH DATASET WILL HAVE ENORMOUS VALUE BEYOND THESE THREE AIMS. WE ARE RECRUITING FROM ESTABLISHED DIAGNOSIS- AND POPULATION-SPECIFIC RESEARCH PROGRAMS; COMBINATION OF THE LONGITUDINAL DATA COLLECTED HERE WITH ADDITIONAL DATA COLLECTED BY THESE PROGRAMS, INCLUDING NEUROIMAGING AND GENETICS, WILL CREATE RICH OPPORTUNITIES FOR SECONDARY AND EXPLORATORY ANALYSES IN SUBGROUPS. FINALLY, THESE DATA WILL BE MADE AVAILABLE TO THE COMMUNITY, IN DEIDENTIFIED FORM IN COLLABORATION WITH THE IMPACT-MH DATA COORDINATING CENTER, FOR EXPLORATORY AND CONFIRMATORY ANALYSIS BY OTHERS.
Department of Health and Human Services
$20.6M
ANTICOAGULATION IN ICH SURVIVORS FOR PREVENTION AND RECOVERY (ASPIRE)
Department of Health and Human Services
$20.2M
YALE TOBACCO CENTER OF REGULATORY SCIENCE
Department of Health and Human Services
$20.2M
VIKTRIY EARLY CLINICAL TRIALS CONSORTIUM (ECTC)
Department of Health and Human Services
$20M
PERUVIAN/BRAZILIAN AMAZON CENTER OF EXCELLENCE IN MALARIA
Department of Health and Human Services
$19.7M
ABCD-USA: NYC RESEARCH PROJECT
Department of Health and Human Services
$19M
REGULATION OF LIVER BY NUCLEAR CA2+ SIGNALING
Department of Health and Human Services
$18.8M
MOLECULAR MECHANISMS OF ARTERIGENESIS
Department of Health and Human Services
$18.6M
CONSUMER ASSESSMENT OF HEALTHCARE PROVIDERS AND SYSTEMS
Department of Energy
$18.4M
TAS::89 0222::TAS; NEW; RELATIVISTIC HEAVY ION PHYSICS; PI - JOHN HARRIS
Department of Energy
$18.4M
RESEARCH IN ELEMENTARY PARTICLES AND INTERACTIONS
Department of Health and Human Services
$18.3M
PREDOCTORAL PROGRAM IN CELLULAR AND MOLECULAR BIOLOGY
Department of Health and Human Services
$17.3M
COVID-19 TESTING AND PREVENTION IN CORRECTIONAL SETTINGS
Department of Health and Human Services
$16.8M
GEORGE M O'BRIEN KIDNEY CENTER AT YALE
Department of Defense
$16M
TOWARDS FAULT-TOLERANCE IN A HARDWARE-EFFICIENT MODULAR ARCHITECTURE
Department of Health and Human Services
$15.3M
THE Y-SCORCH DATA GENERATION CENTER AT YALE FOR SINGLE-CELL OPIOID RESPONSES IN THE CONTEXT OF HIV
Department of Health and Human Services
$15.1M
PROGRAM IN MACROMOLECULAR STRUCTURE, MOTION, CONTROL
Department of Health and Human Services
$15M
PAIN MANAGEMENT COLLABORATORY COORDINATING CENTER (PMC3)
Department of Defense
$15M
MATERIALS LIMITS ON COHERENCE IN CHARGE QUBITS
Department of Health and Human Services
$14.8M
BIOMEDICAL INFORMATICS RESEARCH TRAINING AT YALE
Department of Health and Human Services
$14.8M
YALE CENTER FOR MENDELIAN GENOMICS
Department of Health and Human Services
$14.3M
MOLECULAR BASIS OF VIRAL AND CELLULAR TRANSFORMATION
Department of Defense
$14.2M
ERROR-CORRECTED QUANTUM REGISTERS FOR A MODULAR SUPERCONDUCTING QUANTUM COMPUTER
Department of Health and Human Services
$14.2M
MEDICAL SCIENTIST TRAINING PROGRAM
Department of Health and Human Services
$14M
CELLULAR AND MOLECULAR STUDIES OF RENAL TRANSPORT
Department of Health and Human Services
$14M
GLOBAL HEALTH EQUITY SCHOLARS PROGRAM - D43 FOGARTY TRAINING
Department of Health and Human Services
$13.9M
A PROGRAM FOR INNOVATIVE PET RADIOLIGAND DEVELOPMENT AND APPLICATION - A TRANSLATIONAL TOOLBOX FOR TREATMENTS FOR MENTAL HEALTH
Department of Health and Human Services
$13.8M
YALE TRANSDISCIPLINARY COLLABORATIVE CENTER FOR HEALTH DISPARITIES RESEARCH (YALE-TCC)
National Science Foundation
$13.6M
CENTER FOR INNOVATIVE STRUCTURES AND PHENOMENA
Department of Health and Human Services
$13.5M
VALIDATION OF EARLY PROGNOSTIC DATA FOR RECOVERY OUTCOMES AFTER STROKE FOR FUTURE, HIGHER YIELD TRIALS (VERIFY) - CURRENTLY, 7 MILLION US STROKE SURVIVORS HAVE SIGNIFICANT DISABILITY, MORE THAN HALF WITH RESIDUAL MOTOR DEFICITS. MOTOR FUNCTION, PARTICULARLY OF THE UPPER EXTREMITY (UE), IS CRITICAL FOR REGAINING INDEPENDENCE AFTER STROKE. UE FUNCTION LARGELY DEPENDS ON INTEGRITY OF MOTOR CORTEX AND ITS DESCENDING FIBERS, COLLECTIVELY TERMED THE CORTICOMOTOR SYSTEM (CMS). VALIDATED, CLINICALLY RELEVANT BIOMARKERS THAT IDENTIFY BIOLOGICALLY DISTINCT PATIENT SUBGROUPS ARE CRITICALLY NEEDED, PARTICULARLY FOR THE OFTEN AFFECTED AND FUNCTIONALLY IMPORTANT CMS. THEIR ABSENCE IS A MAJOR OBSTACLE TO DEVELOPING AND PERSONALIZING NEW RECOVERY THERAPIES, ESPECIALLY IN THE EARLY DAYS POST- STROKE. PRESENCE OR ABSENCE OF MOTOR EVOKED POTENTIAL (MEP) RESPONSES TO TMS AND EXTENT OF MRI-MEASURED ACUTE LESION LOAD INVOLVING CORTICOSPINAL TRACT (CST) ARE READY FOR FORMAL VALIDATION. ALSO, THE PREDICT RECOVERY POTENTIAL (PREP)-2 PREDICTION TOOL, WHICH SEQUENTIALLY COMBINES ACUTE CLINICAL INFORMATION AND MEP STATUS, IS PRIMED FOR MULTI-SITE VALIDATION. OUR CURRENT OBJECTIVE, WELL-ALIGNED WITH STROKENET’S, IS TO VALIDATE THE MOST BIOLOGICALLY RELEVANT AND PRIMED BIOMARKERS OF 90-DAY UE MOTOR OUTCOMES AFTER ISCHEMIC STROKE IN THE FIRST LARGE- SCALE, PROSPECTIVE, ACUTE DATASET OF CLINICAL, TRANSCRANIAL MAGNETIC STIMULATION (TMS), AND MRI MEASURES. THE CENTRAL HYPOTHESIS IS THAT PATIENTS HAVE DIFFERENT UE OUTCOMES DEPENDING ON CMS FUNCTION MEASURED WITH TMS, AND ON CST INJURY MEASURED WITH MRI. THE PROPOSED STUDY, “VALIDATION OF EARLY PROGNOSTIC DATA FOR RECOVERY OUTCOMES AFTER STROKE FOR FUTURE, HIGHER YIELD TRIALS” (VERIFY), WILL COLLECT DATA FROM 657 PATIENTS AT 30 US SITES TO ADDRESS THE FOLLOWING SPECIFIC AIMS. AIM 1: TO EXTERNALLY VALIDATE THE RELATIONSHIPS THAT TMS AND MRI BIOMARKERS OF CMS INTEGRITY ACQUIRED < 7 DAYS AFTER STROKE HAVE WITH UE MOTOR IMPAIRMENT OUTCOME AT 90 DAYS AFTER ISCHEMIC STROKE. AIM 2: TO EXTERNALLY VALIDATE THE PREP2 PREDICTION TOOL USED < 7 DAYS AFTER STROKE TO PREDICT 90-DAY UE FUNCTIONAL OUTCOME FOR INDIVIDUAL PATIENTS WITH ISCHEMIC STROKE. OUR MULTI-DIMENSIONAL APPROACH TO UE MOTOR OUTCOMES IS AN INNOVATIVE ADVANCE ON PREVIOUS BIOMARKER STUDIES, WHICH WERE TYPICALLY LIMITED TO PREDICTING OUTCOMES IN ONE OR TWO DOMAINS. WE WILL COMPREHENSIVELY MEASURE UE OUTCOMES 90 DAYS POST-STROKE IN THREE DOMAINS OF MOTOR PERFORMANCE —IMPAIRMENT, FUNCTION, AND USE — IDENTIFIED BY THE WORLD HEALTH ORGANIZATION INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH. OUR CROSS-DISCIPLINARY TEAM HAS ESTABLISHED EXPERTISE IN MULTICENTER ACUTE TRIALS, NEUROPHYSIOLOGY, NEUROIMAGING, AND STROKE RECOVERY AND REHABILITATION. THE RESULTS ARE EXPECTED TO HAVE A POSITIVE IMPACT BECAUSE BIOMARKERS USED IN THE ACUTE STROKE PERIOD TO IDENTIFY PATIENT SUBGROUPS WITH DISTINCT DAY-90 OUTCOMES CAN AID STROKE RECOVERY TRIALS AND INFORM REHABILITATION DECISION-MAKING.
Agency for International Development
$13M
BRINGING RESEARCH TO IMPACT FOR DEVELOPMENT, GLOBAL ENGAGEMENT, AND UTILIZATION (BRIDGE-U) UNDER EXISTING SCIENCE, TECHNOLOGY, INNOVATION, AND PARTNERSHIP ANNUAL PROGRAM STATEMENT APS NO.: 7200AA18APS00003
Department of Health and Human Services
$12.9M
HEAL INITIATIVE: INTEGRATIVE MANAGEMENT OF CHRONIC PAIN AND OUD FOR WHOLE RECOVERY (IMPOWR): RESEARCH CENTERS - THERE IS AN URGENT NEED TO CONDUCT HIGH IMPACT MULTIDISCIPLINARY RESEARCH FOR PATIENTS WITH CHRONIC PAIN (CP) AND OPIOID USE DISORDER (OUD)IN THE SETTINGS WHERE THEY RECEIVE CARE AND IN COLLABORATION WITH STAKEHOLDERS AND PERSONS WITH LIVED EXPERIENCE (PWLE). WE PROPOSE TO CREATE THE INTEGRATIVE MANAGEMENT OF CHRONIC PAIN AND OUD FOR WHOLE RECOVERY– YALE AND ORGANIZATIONS UNITED (IMPOWR- YOU). IMPOWR-YOU IS A MULTIDISCIPLINARY CENTER LED BY ESTABLISHED INVESTIGATORS WITH EXPERTISE STUDYING CP AND OPIOID USE DISORDER/MISUSE (OUD/MISUSE) AND WORKING IN PARTNERSHIP WITH STAKEHOLDERS AND PWLE. WE CONDUCT RESEARCH IN GENERAL MEDICAL SETTINGS (PRIMARY CARE, HOSPITAL) AND SPECIALTY (OPIOID TREATMENT PROGRAMS (OTPS)) WITH A FOCUS ON SUPPORTING THE CAREER DEVELOPMENT OF EARLY STAGE INVESTIGATORS AND THOSE FROM GROUPS TRADITIONALLY UNDERREPRESENTED IN RESEARCH (URG). IMPOWR-YOU IS COMPRISED OF 5 CORES (OPERATIONS, STAKEHOLDER/PWLE, CAREER DEVELOPMENT AND DIVERSITY, PILOT PROJECTS, DATA AND MEASUREMENT), 2 RESEARCH PROJECTS, AND ANNUAL PILOT PROJECTS. OUR RESEARCH, BUILT ON PREVIOUS WORK OF OUR INVESTIGATORS AND STAKEHOLDERS, ADDRESSES CRITICAL ISSUES THAT FACE PRACTITIONERS ACROSS THE HEALTHCARE SYSTEM. PROPOSED STUDIES INCLUDE: 1) IN PRIMARY CARE, COMPARE THE EFFECTIVENESS OF A PHARMACIST LED COLLABORATIVE CARE APPROACH FOR PATIENTS PRESCRIBED LONG-TERM OPIOIDS WHO HAVE CP AND OUD/MISUSE VS. THE PHARMACIST PROGRAM PLUS PATIENT REFERRAL TO A PHONE- DELIVERED, COGNITIVE BEHAVIOR THERAPY (CBT)-BASED PAIN SELF-MANAGEMENT PROGRAM; 2) IN AN OTP TO COMPARE THE EFFECTIVENESS OF A STEPPED CARE MULTIMODAL INTERDISCIPLINARY CP MANAGEMENT THAT INCLUDES CBT, EXERCISE AND STRESS MANAGEMENT TO TREATMENT AS USUAL IN PATIENTS RECEIVING METHADONE OR BUPRENORPHINE; 3. IN YEAR 1 CONDUCT A PILOT TO MODIFY AN OPIOID STEWARDSHIP PROGRAM TO ADDRESS THE NEEDS OF HOSPITALIZED PATIENTS WITH CP AND OUD AND EVALUATE ITS PRELIMINARY EFFICACY. ALL STUDIES INCLUDE OUTCOMES RELATED TO PAIN, OUD, ALCOHOL USE, ANXIETY, DEPRESSIVE SYMPTOMS, SLEEP PROBLEMS AND SOME ASSESS STRESS, STIGMA AND RECOVERY CAPITAL. OUR PILOT PROJECT CORE WILL OVERSEE THE SELECTION OF PILOTS IN YEARS 2-5 TO SUPPORT EARLY STAGE INVESTIGATORS AND COLLABORATIONS WITH STAKEHOLDERS/PWLE. IMPOWR-YOU IS BUILT ON LONG-STANDING MULTIDISCIPLINARY RESEARCH COLLABORATIONS AMONG DIVERSE STAKEHOLDERS, INCLUDING PWLE, EARLY STAGE INVESTIGATORS, URG, HEALTH SYSTEMS, AND ORGANIZATIONS THAT PRODUCE GUIDELINES FOR CP AND OUD/MISUSE. IMPOWR-YOU HAS THE IDEAL MIXTURE OF INVESTIGATORS, INCLUDING LEADERS IN PRIMARY CARE, ADDICTION MEDICINE/PSYCHIATRY, PSYCHOLOGY SPECIALTY CARE, CLINICAL TRIALS, QUALITATIVE RESEARCH AND IMPLEMENTATION SCIENCE; ESTABLISHED RELATIONSHIPS WITH STAKEHOLDERS AND PWLE; A TRACK RECORD OF INNOVATION, LEADERSHIP, COLLABORATION, AND OUTSTANDING PRODUCTIVITY TO CREATE A LEADING CENTER THAT WILL CONTRIBUTE TO ADDRESSING THE UNIQUE NEEDS OF PATIENTS WITH CP AND OUD/MISUSE.
Department of Defense
$12.8M
THE PURPOSE OF THIS AGREEMENT IS TO FUND RESEARCH SUPPORTING THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA) BIOLOGICAL TECHNOLOGIES OFFICES (BTO) HARNESSING ENZYMATIC ACTIVITY FOR BACTERIAL TOXINS (HEALR) PROGRAM.
Department of Energy
$12.6M
TAS::89 0227::TAS RECOVERY ACT HIGH ENERGY PHYSICS RESEARCH, TASKS A, B, C, D, F, G, K AND J
Department of Health and Human Services
$12.3M
CENTER FOR MOLECULAR IMAGING TECHNOLOGY AND TRANSLATION (CMITT)
Department of Health and Human Services
$12.2M
INSTITUTIONAL CAREER DEVELOPMENT CORE
Department of Health and Human Services
$12.1M
ADDRESSING RISK THROUGH COMMUNITY TREATMENT FOR INFECTIOUS DISEASE AND OPIOID USE DISORDER NOW (ACTION) AMONG JUSTICE-INVOLVED POPULATIONS
Department of the Interior
$12.1M
THIS PROJECT IS AIMED AT DEVELOPING A LOW COST NOVEL DEVICE FOR BREAST MRI. MRI IS A PROVEN MODALITY FOR IMAGING CANCERS OF THE BREAST AND THE PRIMARY FACTOR LIMITING ITS WIDESPREAD USE IS ACCESS WHICH IS LIMITED DUE TO THE HIGH COST OF MRI MACHINES AND DIFFICULT SITING DUE TO THEIR LARGE SIZE. IMPROVED ACCESS TO BREAST MRI COULD MAKE ANNUAL SCREENING AVAILABLE FOR THE MAJORITY OF WOMEN AND IN TURN THIS WOULD SAVE MANY LIVES. EARLY DETECTION OF CANCER IS A KEY TO IMPROVED OUTCOMES. INCLUDING BREAST MRIS AS PART OF AN ANNUAL EXAM FOR ALL WOMEN WOULD HAVE A MAJOR POSITIVE OUTCOME ON WOMENS HEALTH. THERE ARE NO SUBRECIPIENTS.
Department of Health and Human Services
$11.9M
MECHANISMS OF SOCIAL ENGAGEMENT IN AUTISM SPECTRUM DISORDERS
Department of Health and Human Services
$11.8M
A TRANSLATIONAL AND NEUROCOMPUTATIONAL EVALUATION OF A D1R PARTIAL AGONIST FOR SCHIZOPHRENIA
Department of Health and Human Services
$11.8M
1/8-PREDICTORS AND MECHANISMS OF CONVERSION TO PSYCHOSIS
Department of Health and Human Services
$11.8M
YALE HEAD AND NECK CANCER SPORE: OVERCOMING TREATMENT RESISTANCE IN HEAD AND NECK CANCER
Department of Defense
$11.6M
POLYCYSTIC KIDNEY DISEASE: A DISORDER OF GLOMERULOTUBULAR SYNCHRONIZATION
Department of Defense
$11.4M
TARGETING BREAST CANCER BRAIN METASTASES WITH AN ANTI-DNA AUTOANTIBODY
Department of Health and Human Services
$11.4M
CLINICIAN SCIENTIST TRAINING IN SUBSTANCE ABUSE RESEARCH
Department of Health and Human Services
$11.2M
RISK STRATIFICATION IN OLDER PERSONS WITH ACUTE MYOCARDIAL INFARCTION: SILVER-AMI
Department of Health and Human Services
$11.2M
DISCOVERY AND ANALYSIS OF THE C. ELEGANS NEURONAL GENE EXPRESSION NETWORK (CENGEN)
Department of Health and Human Services
$11.2M
GENETIC & SOCIAL DETERMINANTS OF HEALTH: CENTER FOR ADMIXTURE SCIENCE AND TECHNOLOGY - PROJECT SUMMARY IT IS IMPERATIVE TO UNDERSTAND THE UNDERLYING SOURCES OF THE LARGE HEALTH DISPARITIES AMONG INDIVIDUALS FROM DIFFERENT RACIAL AND ETHNIC GROUPS LIVING IN THE UNITED STATES (US). COMPLEX RELATIONSHIPS BETWEEN GENETICS AND SOCIAL FACTORS INFLUENCE HEALTH OUTCOMES. APPROXIMATELY 33% OF PEOPLE IN THE US BELONG TO AN ETHNIC MINORITY GROUP AND ~12.5% LIVE BELOW THE FEDERAL POVERTY LINE. HISTORICAL AND RECENT MIXING OF EUROPEANS, NATIVE AMERICANS, AFRICANS AND ASIANS RESULTED IN THE US POPULATION HAVING A RELATIVELY LARGE NUMBER OF ADMIXED INDIVIDUALS WHO CARRY ANCESTRY FROM OUTSIDE THEIR SELF-IDENTIFIED RACE. THE ALL OF US (AOU) PROGRAM AND THE MILLION VETERANS PROGRAM (MVP) INCLUDE GENETIC, HEALTH AND SOCIOECONOMIC INFORMATION ON ALL PARTICIPANTS, AND THEREFORE PROVIDE AN OPPORTUNITY TO IDENTIFY FACTORS CONTRIBUTING TO HEALTH DISPARITIES. HOWEVER, THE AOU PROGRAM AND MVP REQUIRE THEIR DATA TO STAY WITHIN LOCAL HOSTING SITES, THEREFORE CONDUCTING JOINT ANALYSES ON THESE COHORTS REQUIRES THE DEVELOPMENT OF ALGORITHMS THAT ENABLE PRIVACY-PROTECTING DISTRIBUTED COMPUTING (I.E., WITHOUT REVEALING INDIVIDUAL-LEVEL DATA). THERE ARE THREE IMPORTANT GAPS IN UNDERSTANDING GENETIC DETERMINANTS OF HEALTH: 1) MOST STUDIES HAVE BEEN DOMINATED BY EUROPEAN INDIVIDUALS, AND WHILE THEY CONTROL FOR GLOBAL ANCESTRY, THERE IS NO ATTEMPT TO MODEL THE PATCHWORK OF LOCAL ANCESTRY CHARACTERISTIC OF ADMIXED INDIVIDUALS; 2) GWAS ARE PRIMARILY CONDUCTED USING SNPS, WHILE IMPORTANT SOURCES OF ANCESTRY-SPECIFIC GENETIC VARIATION (TANDEM REPEATS (TRS) AND THE MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) INTERVAL) ARE NOT ASSAYED; AND 3) MOST GWAS DO NOT ADJUST FOR SOCIOECONOMIC FACTORS. THE AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS (ACMG) HAS PUBLISHED A LIST OF MEDICALLY ACTIONABLE CANCER AND CARDIOVASCULAR GENES RECOMMENDED FOR RETURN OF INCIDENTAL FINDINGS OF PATHOGENIC VARIANTS TO REDUCE MORBIDITY AND MORTALITY, BUT HAVING MINORITIES EXCLUDED FROM HEALTHCARE FOLLOW UP DUE TO COMMON BARRIERS (E.G., LANGUAGE AND ACCESS) MAKES IT DIFFICULT TO DISTINGUISH BETWEEN THE GENETIC AND SOCIOECONOMIC FACTORS THAT CONTRIBUTE TO DISPARATE HEALTH OUTCOMES. THE GOAL OF THE CAST (CENTER FOR ADMIXTURE SCIENCE AND TECHNOLOGY) PROGRAM IS TO IMPROVE THE CLINICAL UTILITY OF GENETIC INFORMATION FOR ALL POPULATIONS LIVING IN THE US. IN AIM 1, WE WILL DEVELOP AND APPLY MULTIVARIATE MODELS OF DISEASE RISK PREDICTION THAT INCORPORATE LOCAL ANCESTRY, COMPLEX VARIANTS (TRS AND HLA TYPES). IN AIM 2, WE WILL CONDUCT SCALABLE DISTRIBUTED COMPUTING USING DATA FROM MILLIONS OF INDIVIDUALS ACROSS THE AOU AND MVP COMPUTE ENCLAVES. IN AIM 3, WE WILL DEVELOP NEW APPROACHES TO CHARACTERIZE PHENOTYPES USING ELECTRONIC HEALTH RECORDS AND SURVEYS FROM AOU AND MVP, ASSESS THE IMPACT OF INCLUDING SOCIAL DETERMINANTS OF HEALTH IN OUR MODELS, AND PROSPECTIVELY EVALUATE THEM WITH NEW AOU AND MVP PARTICIPANTS. TO ACHIEVE THESE GOALS, WE ASSEMBLED A HIGHLY INTERDISCIPLINARY GROUP OF RESEARCHERS WITH EXPERTISE IN GENETICS, GENOME BIOLOGY, DATA SHARING POLICY AND TECHNOLOGY, HEALTH DISPARITIES, PHENOTYPING, AND STATISTICS.
Department of Health and Human Services
$11.2M
CELLULAR, MOLECULAR, AND FUNCTIONAL IMAGING APPROACHES TO UNDERSTANDING EARLY NEURODEVELOPMENT IN AUTISM
Department of Health and Human Services
$11.2M
A FAIR BRIDGE2AI CENTER (FABRIC) - BRIDGE2AI: A FAIR AI BRIDGE CENTER (FABRIC) OVERALL SUMMARY WE PROPOSE TO DEVELOP A FAIR BRIDGE2AI CENTER (FABRIC) TO ORGANIZE A LARGE CONSORTIUM OF INSTITUTIONS THAT WILL BE GENERATING DATA AND TOOLS TO ENABLE THE APPLICATION OF NOVEL AI ALGORITHMS TO SOLVE BIOMEDICAL OR BEHAVIORAL PROBLEMS AFFECTING HUMAN HEALTH. OUR CENTER’S APPROACH IS TO DEVELOP AN ADMINISTRATIVE CORE THAT, TOGETHER WITH A TEAMING CORE, DESIGNS AND MANAGES STRUCTURAL COMPONENTS OF THE BRIDGE2AI CONSORTIUM WITH A FOCUS ON TEAM SCIENCE AND INCLUSION. THE PRODUCTS AND ACTIVITIES OF EACH OF FOUR CORES ARE LED BY EXPERTS IN THEIR RESPECTIVE FIELDS, AND WHO HAVE AN EXTENSIVE TRACK RECORD OF WORKING TOGETHER IN LARGE NIH-FUNDED INITIATIVES, SUCH AS BD2K, ALL OF US, ETC. THE ADMINISTRATIVE AND TEAMING CORES ARE BASED AT THE UNIVERSITY OF CALIFORNIA SAN DIEGO. THE ETHICS CORE, LED BY VANDERBILT UNIVERSITY, WILL OVERSEE ALL ETHICAL, LEGAL, AND SOCIAL IMPLICATIONS (ELSI), GENERATE GUIDELINES AND ASSESS FAIRNESS IN DATA FROM DATA GENERATION PROJECT (DGP) AND OTHER CONSORTIUM PRODUCTS. THE STANDARDS CORE, LED BY UNIVERSITY OF TEXAS HEALTH, WILL ENSURE THAT ALL PRODUCTS AND ACTIVITIES FOLLOW THE FAIR (FINDABLE, ACCESSIBLE, INTEROPERABLE, REUSABLE) PRINCIPLES AND ARE HARMONIZED/STANDARDIZED TO AGREED UPON STANDARDS. THE TOOL OPTIMIZATION CORE, LED BY THE BROAD INSTITUTE, WILL USE ITS EXPERIENCE DEVELOPING LARGE- SCALE SOFTWARE TO BUILD A PLATFORM FOR THE WHOLE CONSORTIUM, WHERE CORES AND DGPS CAN HAVE THEIR PRODUCTS AVAILABLE FOR OTHER RESEARCHERS. IT WILL ALSO OPTIMIZE VARIOUS TOOLS THAT ARE DEEMED USEFUL FOR BRIDGE2AI. THE SKILLS AND WORKFORCE DEVELOPMENT WILL DEVELOP AND DELIVER EDUCATIONAL MATERIALS AND ACTIVITIES FOR THE WHOLE CONSORTIUM AND OPTIMIZE SOFTWARE DEVELOPED BY OTHERS. A SPECIAL EMPHASIS FOR FABRIC IS INCLUSION, AS OUR VISION IS FOR A NOVEL TYPE OF COORDINATING CENTER WHERE THERE IS NO SINGLE POINT OF CONTROL AND IN WHICH TRANSACTIONS (E.G., DATA ACCESS, DATA USE) ARE IMMUTABLY RECORDED IN AN EASY-TO-ACCESS LEDGER THAT IS VIEWABLE BY ALL. FABRIC IS DESIGNED SO THAT VARIOUS THREADS IN CORES AND DGPS ARE INTERWOVEN INTO A DURABLE, SUSTAINABLE CENTER FOR THE BRIDGE2AI CONSORTIUM.
Department of Health and Human Services
$11M
YALE CENTER FOR MENDELIAN DISORDERS
Department of Health and Human Services
$11M
TRAINING IN RESPIRATORY BIOLOGY AND PATHOBIOLOGY
Department of Health and Human Services
$10.9M
OPTIMIZING ENGAGEMENT IN DISCOVERY OF MOLECULAR EVOLUTION OF LOW GRADE GLIOMA (OPTIMUM) - PROJECT SUMMARY LOWER GRADE (WORLD HEALTH ORGANIZATION (WHO) GRADE II/III) GLIOMA (LGG), A MALIGNANT TUMOR OF THE BRAIN, IS A UNIFORMLY FATAL DISEASE OF YOUNG ADULTS. THE OPTIMAL CLINICAL MANAGEMENT FOR LGG REMAINS UNKNOWN. A COMPREHENSIVE GENOMIC CHARACTERIZATION OF THE EVOLUTION FROM PRIMARY LGG TO RECURRENCE IS REQUIRED TO BEGIN TO ADDRESS THE LGG KNOWLEDGE GAP; OPTIMIZING THE ENGAGEMENT OF LGG PATIENTS IN THIS EFFORT IS CRITICAL TO THE SUCCESS OF THIS PROCESS. USING OUR INTERNATIONAL LOW GRADE GLIOMA REGISTRY AS A STARTING POINT, WE WILL CONSTRUCT A COMMUNITY OF 700 LGG PATIENTS WHO HAVE UNDERGONE SURGICAL RESECTION AT TIME OF DIAGNOSIS AND AT TIME OF RECURRENCE AND WANT TO PARTICIPATE IN RESEARCH. WE WILL USE BOTH HOSPITAL-BASED AS WELL AS WEB- AND SOCIAL MEDIA-BASED PATIENT ENGAGEMENT EFFORTS AND ADAPT PRE-EXISTING RESOURCES DEVELOPED AT YALE INCLUDING HUGO PHR, A SECURE CLOUD-BASED PERSONAL HEALTH RECORD PLATFORM THAT ALLOWS SECURE AND PERMISSION-BASED MOVEMENT OF DATA BI-DIRECTIONALLY BETWEEN PATIENTS AND RESEARCHERS AND ARCHETYP, A YALE-DEVELOPED SOFTWARE THAT ASSISTS PATIENTS IN THE LOCATION OF CLINICAL TRIALS. WE HYPOTHESIZE THAT LGG PATIENT ENGAGEMENT AND SATISFACTION (AND THUS OVERALL PARTICIPATION) IN GENOMIC CHARACTERIZATION STUDIES WILL BE IMPROVED BY 1) THE ABILITY TO OBTAIN AND SHARE MEDICAL RECORD DATA WITH RESEARCHERS, 2) THE AVAILABILITY OF BI-DIRECTIONAL COMMUNICATION BETWEEN STUDY AND PATIENTS REGARDING STUDY FOCUS, PROGRESS, OUTCOMES AS WELL AS PATIENT SPECIFIC RESULTS, 3) IMPROVED MESSAGING AND EDUCATION REGARDING STUDY AND PATIENT GOALS WITH RESPECT TO GENOMIC CHARACTERIZATION OF PATIENT MATERIALS. WE ALSO PROPOSE THAT THE KNOWLEDGE GAINED IN THIS APPLICATION WILL PROVIDE A SIGNIFICANT IMPROVEMENT IN THE CARE OF LGG PATIENTS.
Department of Health and Human Services
$10.7M
METABOLIC BASIS OF B CELL LINEAGE LEUKEMIA RELAPSE
Department of Health and Human Services
$10.4M
HOST CELL SIGNALING PATHWAYS INDUCED BY SALMONELLA
Department of Health and Human Services
$10.1M
SYSTEMS ANALYSIS OF PHENOTYPIC SWITCH IN CONTROL OF CANCER INVASION
Environmental Protection Agency
$10M
THIS PROPOSED PROJECT FOCUSES ON ESTIMATING HOW KEY FACTORS CONTRIBUTING TO EMISSIONS, AIR QUALITY AND HEALTH AFFECT REGIONAL AND LOCAL DIFFERENCES I
Department of Health and Human Services
$10M
YALE-SCORE ON SEX DIFFERENCES IN ALCOHOL USE DISORDER
Department of Health and Human Services
$10M
NEUROEXPLORER: ULTRA-HIGH PERFORMANCE HUMAN BRAIN PET IMAGER FOR HIGHLY-RESOLVED IN VIVO IMAGING OF NEUROCHEMISTRY
Department of Health and Human Services
$9.9M
TRANSCRIPTIONAL ATLAS OF HUMAN BRAIN DEVELOPMENT
Department of Health and Human Services
$9.9M
INTERDISCIPLINARY IMMUNOLOGY TRAINING PROGRAM
Department of Health and Human Services
$9.8M
INDUCING PROTEIN DEGRADATION: A NEW PHARMACEUTICAL PARADIGM
Department of Health and Human Services
$9.7M
MECHANISMS OF BILE SECRETION AND CHOLESTASIS
Department of Health and Human Services
$9.5M
INTERDISCIPLINARY HIV PREVENTION TRAINING PROGRAM
Department of Health and Human Services
$9.5M
M-SCORCH: METHAMPHETAMINE USE DISORDER DATA GENERATION CENTER FOR SINGLE CELL OPIOID RESPONSES IN THE CONTEXT OF HIV - PROJECT SUMMARY HIV AND METHAMPHETAMINE (MA) USE ARE GLOBAL HEALTH PROBLEMS WITH DEVASTATING HUMAN AND SOCIETAL CONSEQUENCES. HIV AND METHAMPHETAMINE USE ALSO PRODUCE INDEPENDENT AND ADDITIVE IMPAIRMENTS IN NEUROCOGNITION, AND CURRENT CLINICAL AND BASIC SCIENCE RESEARCH SUGGEST COMPLEX AND CURRENTLY INADEQUATELY UNDERSTOOD INTERACTIONS BETWEEN HIV AND MA PATHOPHYSIOLOGIES. WE THEREFORE PROPOSE TO CONDUCT COMPREHENSIVE CHARACTERIZATION, AT THE SINGLE CELL/NUCLEAR LEVEL, OF HUMAN BRAIN TISSUE AND REGIONALLY SPECIFIED ORGANOIDS DERIVED FROM HUMAN INDUCED PLURIPOTENT STEM CELLS. FOR THESE SINGLE NUCLEAR (SN)RNA-SEQ AND SNATAC-SEQ ANALYSES, WE WILL SAMPLE 3 BRAIN REGIONS (PREFRONTAL CORTEX, VENTRAL STRIATUM, AND BASOLATERAL AMYGDALA) CRITICAL FOR THE NEUROBIOLOGICAL RESPONSE TO MA USE IN 20 BRAINS FROM EACH OF TWO DONOR GROUPS, HIV+MA+ AND HIV-MA+. THESE DATA GENERATION EFFORTS WILL COMPLEMENT ONGOING EFFORTS IN THESE SAME BRAIN REGIONS FROM HIV-MA- AND HIV+MA- DONORS AND ALLOW US TO ELUCIDATE DIFFERENCES IN GENE EXPRESSION AND KEY BIOLOGICAL PATHWAYS THAT OCCUR IN RESPONSE TO MA USE, HIV, OR THE COMBINATION OF THE TWO. IN ADDITION, WE WILL ASSAY BRAIN CELL TYPES FOR HIV TRANSCRIPTS, ALLOWING US TO IDENTIFY CELLULAR RESERVOIRS OF HIV IN DONOR BRAINS. THESE EFFORTS WILL BE AIDED BY THE USE OF HUMAN CORTICAL ORGANOID AND MEDIAL GANGLIONIC EMINENCE ORGANOID CULTURES, WHICH OFFER COMPLEX, REGION-MATCHED MODEL SYSTEMS RECAPITULATING IN VIVO-LIKE CELLULAR DIVERSITY AND MICROENVIRONMENTS WITHOUT POTENTIALLY CONFOUNDING FACTORS INCLUDING PATIENT HISTORY, VARYING CO-MORBIDITIES, PROLONGED POSTMORTEM INTERVALS, OR TISSUE DEGRADATION. WE WILL THEN APPLY CUTTING EDGE AND NOVEL DATA ANALYSIS PIPELINES TO INTEGRATE SNRNA-SEQ AND SNATAC-SEQ DATA AND IDENTIFY CELL POPULATION AND GENE EXPRESSION DIFFERENCES BETWEEN CELL CLUSTERS (I.E., PUTATIVE CELL TYPES) IN DIFFERENT CONDITIONS. THESE DATA WILL ALSO BE INTEGRATED WITH EXTERNAL DATASETS FROM THE SCORCH CONSORTIUM AND OTHER MULTI-OMIC DATA INCLUDING GENOTYPE, RNA-SEQ, HIC, CHIP-SEQ, AND ATAC-SEQ DATA FROM BOTH HEALTHY SUBJECTS AND SUBJECTS WITH HIV INFECTION, NEUROLOGICAL DISEASE, OR A HISTORY OF DRUG ABUSE. FINALLY, WE WILL USE MULTIPLEXED IMMUNOHISTOCHEMISTRY AND SINGLE MOLECULAR FLUORESCENT IN SITU HYBRIDIZATION TO VALIDATE THE CELL TYPE SPECIFIC EXPRESSION AND CO-EXPRESSION OF CANDIDATE GENES, BIOLOGICAL PROCESSES, AND GENE REGULATORY NETWORKS IMPLICATED IN THE ETIOLOGY OF HIV OR MA PATHOPHYSIOLOGY. ALL DATA GENERATION PROTOCOLS AND DATA ANALYSIS TOOLS WILL BE MADE FREELY AVAILABLE TO THE RESEARCH COMMUNITY, AND ALL DATA GENERATED WILL BE PROVIDED AS BOTH RAW AND PROCESSED RESOURCES. TAKEN TOGETHER, THE PROPOSED EXPERIMENTS WILL GENERATE INVALUABLE RESOURCES AND OFFER NEW BIOLOGICAL INSIGHTS INTO THE HUMAN BRAIN AND ITS DISORDERS.
Department of Health and Human Services
$9.2M
WEST CAMPUS B3(WB3)VIVARIUM
Department of Health and Human Services
$9.2M
INTERDEPARTMENTAL NEUROSCIENCE PROGRAM
Department of Health and Human Services
$9.1M
STRUCTURE AND FUNCTION OF ARP 2/3 COMPLEX
Department of Health and Human Services
$9M
MOLECULAR AND CELLULAR BASIS OF COGNITIVE AGING IN PREFRONTAL CORTICAL NETWORKS
Department of Health and Human Services
$9M
YALE COOPERATIVE HEMATOLOGY SPECIALIZED CORE CENTER
Department of Health and Human Services
$9M
MICROBIAL CHEMICAL SENSING AND HOST RESPONSES - SUMMARY. THE TENS OF THOUSANDS OF MICROBIAL METABOLITES PRODUCED BY THE TRILLIONS OF BACTERIAL CELLS THAT COLONIZE OUR INTESTINES (OUR MICROBIOTA) ARE POORLY UNDERSTOOD, AND CURRENT ESTIMATES SUGGEST THAT WE ONLY KNOW THE BIOLOGICAL FUNCTIONS OF 0.1% OF ALL SMALL MOLECULES DERIVED FROM THE MICROBIOTA. SOME OF THE METABOLITES IN THIS SO CALLED “DARK MATTER” OF THE METABOLOME WILL UNDOUBTEDLY HAVE PROFOUND IMPACTS ON HUMAN PHYSIOLOGY. HERE, WE WILL ESTABLISH HOW THE HUMAN MICROBIOME “COMMUNICATES” WITH THE HOST VIA DARK-MATTER-DERIVED MOLECULAR MODULATION OF HOST G PROTEIN-COUPLED RECEPTORS (GPCRS), INCLUDING GPCR SIGNALING EFFECTS MEDIATED BY NOVEL SMALL MOLECULES ENCODED BY THE MICROBIOTA (AIM 1A), GPCR SIGNALING EFFECTS DERIVED FROM ENDOGENOUS HOST CHEMICALS (AIM 1B), AND GUT BACTERIAL TRANSFORMATIONS OF GPCR-TARGETED MEDICAL DRUGS THAT REWIRE CHEMICAL SIGNALING PROGRAMS AT THE HOST-MICROBIOTA INTERFACE (AIM 2). A MAJOR FOCUS WILL BE THE STRUCTURAL, FUNCTIONAL, AND BIOSYNTHETIC CHARACTERIZATION OF NOVEL METABOLITES ASSOCIATED WITH “ORPHAN” GPCR SIGNALING WHERE ONLY LIMITED CHEMICAL AND BIOLOGICAL INFORMATION IS CURRENTLY AVAILABLE. OUR PROPOSAL TAKES ADVANTAGE OF THE RESULTS FROM TWO HIGH-THROUGHPUT SCREENS AND ONE TARGETED SCREEN, WHICH EACH FOCUSED ON DIFFERENT ASPECTS OF HOW MICROBIAL OR HOST METABOLISM IMPACTS HOST GPCR SIGNALING AT A DETAILED MOLECULAR LEVEL. IN PRELIMINARY HIGH-THROUGHPUT STUDIES: 1) WE HAVE ANALYZED ~150 DIVERSE HUMAN GUT BACTERIA FOR SECRETION OF METABOLITES THAT ACTIVATE CONVENTIONAL GPCRS (314 GPCRS) USING A HIGH-THROUGHPUT GPCR SCREENING SYSTEM (AIM 1A). WE HAVE CHARACTERIZED BACTERIAL METABOLITES IDENTIFIED BY THIS SCREEN THAT ACTIVATE THREE ORPHAN GPCRS TO DATE AND HAVE THUS ESTABLISHED A PIPELINE FOR “GPCR DEORPHANIZATION.” 2) WE HAVE SCREENED HUMAN TISSUES FOR SMALL MOLECULES THAT ACTIVATE “ORPHAN” GPCRS WITH NO REPORTED LIGAND INFORMATION AVAILABLE (AIM 1B), PROVIDING A BASIS TO ELUCIDATE THE STRUCTURE AND DISTRIBUTION OF ENDOGENOUS ORPHAN GPCR SIGNALS. 3) WE HAVE EVALUATED THE PROCESSING OF 271 FDA-APPROVED DRUGS (INCLUDING 62 GPCR-TARGETED DRUGS) BY A PANEL OF DOZENS OF GUT MICROBIOTA-DERIVED BACTERIA. THIS PRELIMINARY DATA INCLUDES 585,000 DRUG-BY-MICROBIOTA MEASUREMENTS. MANY DRUG METABOLISM PRODUCTS AND BACTERIAL RESPONSES TO DRUGS CAN BE OBSERVED IN THE METABOLOMICS DATA, GUIDING THE DISCOVERY OF NOVEL GPCR DRUG TRANSFORMATIONS AND “SPECIALIZED” METABOLITES FROM THE GUT MICROBIOTA WHOSE PRODUCTION IS INDUCED IN RESPONSE TO GPCR DRUGS (AIM 2). THE PROPOSED STUDIES WILL REPRESENT A HERETOFORE UNPRECEDENTED STRUCTURE-FUNCTION-BASED EXPLORATION OF THE “DARK MATTER” OF THE MICROBIOTA METABOLOME AND HOW IT IS “SENSED” BY THE HOST. SUCH STUDIES MAY ILLUMINATE NOVEL GPCR- AND MICROBIOTA-TARGETED THERAPEUTIC STRATEGIES FOR A DIVERSITY OF HUMAN DISEASES.
Department of Health and Human Services
$8.9M
PRION PROTEIN IN ALZHEIMER'S DISEASE PATHOPHYSIOLOGY
Department of Health and Human Services
$8.8M
LINKS BETWEEN PRODUCTION AND PERCEPTION IN SPEECH
Department of Health and Human Services
$8.7M
LABORATORY, DATA ANALYSIS, AND COORDINATING CENTER (LDACC) FOR THE DEVELOPMENTAL HUMAN GENOTYPE-TISSUE EXPRESSION PROJECT - PROJECT ABSTRACT WE PROPOSE TO ESTABLISH THE LABORATORY, DATA ANALYSIS, AND COORDINATING CENTER (LDACC) FOR THE DEVELOPMENTAL GENOTYPE-TISSUE EXPRESSION (DGTEX) PROJECT TO GENERATE, ANALYZE, AND INTEGRATE MULTIMODAL GENOMIC DATA FROM VARIOUS TISSUES, WITH EMPHASIS ON MULTIPLE BRAIN REGIONS, ACROSS 4 AGE GROUPS: INFANCY, EARLY CHILDHOOD, LATE CHILDHOOD AND ADOLESCENCE. WE WILL DEVELOP AN ATLAS THAT INTEGRATES GENOTYPING DATA AND FUNCTIONAL GENOMIC DATA TO HELP PREDICT FUNCTIONAL IMPACT OF NONCODING GENOMIC VARIANTS, BOTH COMMON AND RARE ON GENE EXPRESSION. OUR PROJECT WILL ADDRESS TWO KEY KNOWLEDGE GAPS. FIRST, LARGE-SCALE EFFORTS BY GTEX AND OTHER CONSORTIA HAVE FOCUSED ON ADULT OR PRENATAL AGES AND ONLY TO A LIMITED EXTENT, ON THE POSTNATAL DEVELOPMENTAL AGES FROM BIRTH TO ADOLESCENCE, CRITICAL PERIODS BECAUSE HUMANS HAVE PROLONGED POSTNATAL DEVELOPMENT, PARTICULARLY PROMINENT IN THE BRAIN. SECOND, RESOLUTION AT THE LEVEL OF SPECIFIC CELL TYPES IN LACKING IN MANY STUDIES. STUDYING POSTNATAL DEVELOPMENT AT THE LEVEL OF SPECIFIC CELL TYPES IS CRITICAL BECAUSE THE EFFECTS OF GENETIC VARIANTS ON GENE REGULATION ARE OFTEN CELL-TYPE SPECIFIC. TO ADDRESS THESE CRITICAL KNOWLEDGE GAPS, WE PROPOSE TO 1) CREATE AN ATLAS OF PEDIATRIC TISSUE GENE EXPRESSION IN BULK TISSUES AND SINGLE CELL POPULATIONS, 2) ANALYZE DIFFERENCES IN GENE EXPRESSION, REGULATION, AND KNOWN EXPRESSION QTLS AND SPLICING QTLS ACROSS POSTNATAL HUMAN DEVELOPMENT, AND 3) CREATE AND MAKE AVAILABLE A BIOBANK OF AS MANY TISSUES AS POSSIBLE (UP TO 50 TISSUES PER DONOR), AND ASSOCIATED DATA FOR FURTHER CHARACTERIZATION. 4) DEVELOP A DATA PORTAL FOR DATA DISSEMINATION AS WELL AS INTEGRATION OF OUR DATA WITH GENOTYPE TISSUE EXPRESSION (GTEX), BRAIN INITIATIVE CELL CENSUS NETWORK (BICCN) AND OTHER CONSORTIA. BY SO DOING, WE WILL RADICALLY EXPAND UPON EARLIER EFFORTS BY GTEX AND CREATE A COMPREHENSIVE AND BROADLY AVAILABLE COMMUNITY RESOURCE ON HUMAN DEVELOPMENTAL TISSUES, TO HELP DRIVE RESEARCH FORWARD IN MULTIPLE RESEARCH FIELDS, AND GENERALLY ANY DISEASE.
Department of Health and Human Services
$8.7M
CHRONIC ALCOHOL AND BRAIN STRESS CIRCUIT RESPONSE
Department of Health and Human Services
$8.6M
NOVEL DNA REPAIR INHIBITORS FOR CANCER THERAPY
Department of Health and Human Services
$8.6M
FATTY ACID AMIDE HYDROLASE (FAAH) INHIBITOR TREATMENT OF CANNABIS USE DISORDER (CUD)
National Science Foundation
$8.6M
A SYSTEMS APPROACH TO THE DEVELOPMENT AND FUNCTION OF C4 PHOTOSYNTHESIS
Department of Health and Human Services
$8.5M
SILENT ALLOSTERIC MODULATION OF MGLUR5 FOR SAFE AND EFFECTIVE THERAPY OF ALZHEIMER'S DISEASE
Department of Health and Human Services
$8.4M
STRATEGIES TO OVERCOME IMMUNE RESISTANCE IN HEAD AND NECK CANCERS
Department of Energy
$8.4M
OXOMANGANESE CATALYSTS FOR SOLAR FUEL PRODUCTION
Department of Health and Human Services
$8.4M
UNDERSTANDING HOW MEMBRANE COMPOSITION DIRECTS MEMBRANE PROTEIN STRUCTURE AND FUNCTION - THE GOAL OF THIS INTERDISCIPLINARY TEAM SCIENCE PROPOSAL IS TO EXTEND AND INFORM BIOCHEMICAL AND STRUCTURAL BIOLOGY APPROACHES FOR STUDYING MEMBRANE PROTEINS BY UNDERSTANDING HOW THEIR NATIVE ENVIRONMENTS DEFINE STRUCTURE AND FUNCTION. TO DATE, THE MAJORITY OF MECHANISTIC STUDIES OF INTEGRAL MEMBRANE PROTEINS (IMPS) HAVE NOT CAPTURED THE PROPERTIES AND FUNCTIONAL CONTRIBUTIONS OF THE MEMBRANES IN WHICH THE IMPS ARE EMBEDDED. THE CENTRAL GOAL OF OUR COLLABORATIVE TEAM IS TO DEVELOP NEW TECHNOLOGIES AND APPROACHES THAT WILL ALLOW US TO: I.) DEFINE LIPID COMPONENTS AND PROTEIN CO-RECEPTOR COMPONENTS OF FUNCTIONAL COMPLEXES; II.) EVALUATE THE ROLE OF THE LOCAL MEMBRANE ENVIRONMENT IN FUNCTION AND REGULATION OF THE IMPS; AND III.) DETERMINE THE STRUCTURES OF THESE ASSEMBLIES. DRIVEN – AND MADE POSSIBLE – BY THE RECRUITMENT OF SIX KEY JUNIOR FACULTY TO THE DEPARTMENTS OF PHARMACOLOGY AND CELL BIOLOGY OVER THE PAST 5 YEARS, WE HAVE ASSEMBLED AN INTERDISCIPLINARY TEAM WITH SHARED INTEREST IN TRANSMEMBRANE PROTEIN STRUCTURE AND FUNCTION. OUR TEAM MEMBERS BRING COMPLEMENTARY EXPERTISE TO THE PROJECT WITH SKILLS IN CRYO ELECTRON MICROSCOPY (CRYOEM), TOP-DOWN AND BOTTOM-UP MASS SPECTROMETRY (MS), MULTI-OMIC ANALYSIS, OPTICAL IMAGING, BIOCHEMISTRY, AND CELLULAR SIGNALING. WE ARE VERY WELL PLACED TO MAKE UNIQUE ADVANCES IN UNDERSTANDING MEMBRANE PROTEINS INVOLVED IN REGULATION OF BACTERIAL LIPOPOLYSACCHARIDE SYNTHESIS, INSECT OLFACTION, MAMMALIAN ION CHANNELS, AND MAMMALIAN RECEPTORS IN THE G PROTEIN-COUPLE RECEPTOR (GPCR), FRIZZLED, AND RECEPTOR TYROSINE KINASE FAMILIES. OUR SPECIFIC AIMS ARE: 1: IDENTIFY NATIVE ENVIRONMENTS OF INTEGRAL MEMBRANE PROTEINS TO ACHIEVE THIS, WE WILL IDENTIFY NEW MEMBRANE-ACTIVE COPOLYMERS THAT EFFICIENTLY EXTRACT IMPS OF INTEREST, AND USE STATE-OF-THE-ART LIPIDOMICS, PROTEOMICS, AND NATIVE MASS SPECTROMETRY TO ELUCIDATE THE MOLECULAR COMPONENTS OF THE PROTEIN’S MEMBRANE ENVIRONMENT. 2: UNDERSTAND HOW THE NATIVE MEMBRANE ENVIRONMENT MODULATES OR DETERMINES MEMBRANE PROTEIN FUNCTION USING A WIDE VARIETY OF ASSAYS – TAILORED TO EACH IMP – WE WILL ASK HOW THE SPECIFIC MEMBRANE ENVIRONMENT IDENTIFIED IN AIM 1 INFLUENCES IMP ACTIVITY AND OLIGOMERIZATION. WE WILL ALSO USE LIMITED PROTEOLYSIS AND H/D EXCHANGE MASS SPECTROMETRY APPROACHES TO ASSESS THE INFLUENCE OF THE MEMBRANE COMPOSITION ON CONFORMATION AND STRUCTURAL DYNAMICS 3: DETERMINE STRUCTURES OF MEMBRANE PROTEINS AND COMPLEXES IN NATIVE MEMBRANE ENVIRONMENTS WE WILL DETERMINE STRUCTURES OF THE TARGET IMPS IN DEFINED MEMBRANE ENVIRONMENTS USING CRYOEM, TO ASK HOW KNOWN SPECIFIC IMP-ASSOCIATED LIPIDS AND OTHER COMPONENTS INTERACT WITH AND MODULATE IMP STRUCTURE.
Department of Health and Human Services
$8.3M
YALE ALZHEIMER DISEASE RESEARCH CENTER
Department of Health and Human Services
$8.2M
PREDOCTORAL TRAINING PROGRAM IN GENETICS
Department of Health and Human Services
$8.2M
YOUNG WOMEN WITH ACUTE MYOCARDIAL INFARCTION
Department of Health and Human Services
$8.2M
TRAINING PROGRAM IN CHILDHOOD NEUROPSYCHIATRIC DISORDERS
Department of Health and Human Services
$8.2M
FYN INHIBITION BY AZD0530 FOR ALZHEIMERS DISEASE
Department of Health and Human Services
$8.1M
REGULATION OF SALMONELLA VIRULENCE BY THE PHOP PROTEIN
Department of Health and Human Services
$8.1M
GENOME-WIDE DISCOVERY AND TRANSLATIONAL RESEARCH FOR NEURAL REPAIR
National Science Foundation
$8.1M
NEURONEX: THE FABRIC OF THE PRIMATE NEOCORTEX AND THE ORIGIN OF MENTAL REPRESENTATIONS. FROM TRANSCRIPTOMICS TO SINGLE NEURONS AND NEURONAL NETWORKS.
Department of Health and Human Services
$7.9M
UNDERSTANDING SIGNALING BY NON-CANONICAL RECEPTOR TYROSINE KINASES
Department of Health and Human Services
$7.9M
PREDICTIVE PERSONALIZED PUBLIC HEALTH (P3H): A NOVEL PARADIGM TO TREAT INFECTIOUS DISEASE
Department of Health and Human Services
$7.9M
ORIGIN OF CORTICAL SPECIES-SPECIFIC DISTINCTIONS
Department of Health and Human Services
$7.9M
PRISON INTERVENTIONS AND HIV PREVENTION COLLABORATION
Department of Health and Human Services
$7.9M
FUNCTIONAL GENOMICS OF HUMAN BRAIN DEVELOPMENT
Department of Health and Human Services
$7.7M
ALCOHOL AND MULTISUBSTANCE USE IN THE VETERANS AGING COHORT STUDY
Department of Health and Human Services
$7.7M
EMERGING WATER CONTAMINANTS: INVESTIGATING AND MITIGATING EXPOSURES AND HEALTH RISKS - OVERALL SUMMARY/ABSTRACT THE YALE SUPERFUND RESEARCH AND TRAINING PROGRAM (YSRTP) IS DRIVEN BY REGULATORY AND COMMUNITY-BASED CONCERNS ABOUT EMERGING CONTAMINANTS THAT AFFECT WATER RESOURCES AND DRINKING WATER SUPPLIES AT MULTIPLE SITES IN THE US. THE YSRTP HAS CHOSEN TO STUDY 1,4-DIOXANE (1,4-DX) BECAUSE OF ITS COMMON OCCURRENCE IN SUPERFUND SITES AND DRINKING WATER SUPPLIES, AND ITS USEPA AND IARC CLASSIFICATION AS A POSSIBLE HUMAN CARCINOGEN. THE CARCINOGENIC MECHANISM IN THE LIVER IS UNKNOWN AND ITS INTERACTION WITH CO-OCCURRING AND CARCINOGENIC WATER CONTAMINANTS (1,1,1-TRICHLOROETHANE, 1,1,1-TRICHLOROETHYLENE, AND 1,1-DICHLOROETHANE) HAS NEVER BEEN EVALUATED IN EITHER ANIMALS OR HUMANS. GIVEN THAT LIVER CANCER INCIDENCE RATES HAVE MORE THAN TRIPLED SINCE 1980, THERE IS AN URGENT NEED TO EVALUATE WHETHER EMERGING WATER CONTAMINANTS, SUCH AS 1,4-DX, MAY BE CONTRIBUTING TO THIS INCREASE. IMPORTANTLY, A LACK OF BIOMARKERS OF EXPOSURE TO OR THE BIOLOGICAL EFFECTS OF 1,4 -DX HAVE HAMPERED EPIDEMIOLOGIC STUDIES, RISK ASSESSMENT AND SETTING STANDARDS FOR THE CONTAMINANT. IN ADDITION, THE HIGH POLARITY AND LOW BIODEGRADABILITY OF 1,4-DX RESTRICT THE ABILITY TO REMOVE IT FROM AQUIFER SYSTEMS OR DRINKING WATER. INDEED, AVAILABLE TREATMENT TECHNOLOGY IS BOTH EXPENSIVE AND NOT READILY APPLIED TO WATER SUPPLIES. THE YSRTP WILL FOSTER PROBLEM-BASED, SOLUTION-ORIENTED RESEARCH RELATED TO 1,4-DX AND ITS CO-OCCURRING CONTAMINANTS THROUGH INNOVATIVE APPROACHES TO EVALUATE ENVIRONMENTAL OCCURRENCE AND HUMAN EXPOSURE, UNDERSTAND THE UNDERLYING BASIS OF ADVERSE HEALTH EFFECTS, PROVIDE COST-EFFECTIVE REMEDIAL MITIGATION SOLUTIONS AND ULTIMATELY SET THE STAGE FOR IMPROVED REGULATION OF THIS EMERGING CONTAMINANT. THE YSRTP WILL CARRY OUT HIGHLY INTERACTIVE PROJECTS TO: (A) EXAMINE THE HEALTH EFFECTS AND BIOMARKERS OF EXPOSURE/EFFECT TO 1,4-DX (ALONE AND AS A MIXTURE WITH ITS CO-OCCURRING CONTAMINANTS) IN ANIMAL MODELS AND HUMANS, AND (B) DEVELOP SYSTEMS TO MONITOR AND MITIGATE HUMAN EXPOSURE TO 1,4-DX IN WATER. THE BIOMEDICAL SCIENCE RESEARCH PROJECTS WILL ELUCIDATE THE MECHANISM(S) ASSOCIATED WITH 1,4-DX LIVER TOXICITY AND CARCINOGENESIS IN MOUSE AND ZEBRAFISH MODELS (PROJECT 1), AND EXPOSURE ASSESSMENT AND EARLY BIOLOGIC RESPONSES TO 1,4-DX IN HUMAN POPULATIONS (PROJECT 2). THE ENVIRONMENTAL SCIENCE AND ENGINEERING RESEARCH PROJECTS WILL CREATE HIGHLY-SENSITIVE AND SELECTIVE ELECTROCHEMICAL SENSORS FOR ON-SITE, REAL-TIME DETECTION OF 1,4-DX (PROJECT 3) AND DEVELOP INNOVATIVE ADVANCED OXIDATION PROCESSES FOR MITIGATION TECHNOLOGY (PROJECT 4). SUCCESSFUL COMPLETION OF THESE INNOVATIVE STUDIES WILL MAKE A SIGNIFICANT POSITIVE HEALTH IMPACT BY MORE CLEARLY DEFINING THE HEALTH RISKS OF 1,4-DX, ELUCIDATING BIOMARKERS OF EXPOSURE, AND ESTABLISHING EFFECTIVE NEW WAYS TO MONITOR AND MITIGATE THIS IMPORTANT EMERGING CONTAMINANT. OUR SYSTEMS APPROACH INTEGRATES AND LINKS THE RESEARCH PROJECTS WITH THE DEVELOPMENT OF EFFECTIVE COMMUNICATION AND EDUCATION OF STAKEHOLDERS, AND TRAINING OF FUTURE SCIENTISTS TO ENSURE THE PROGRAM HAS A FAR- REACHING IMPACT ON HOW EMERGING CONTAMINANTS ARE ADDRESSED BOTH IN THE US AND GLOBALLY.
Department of Health and Human Services
$7.7M
MODERNIZATION OF THE YALE PET CORE - POSITRON EMISSION TOMOGRAPHY (PET) IS A POWERFUL IMAGING MODALITY THAT ENABLES VISUALIZATION AND QUANTIFICATION OF BIOLOGICAL FUNCTIONS USING RADIOPHARMACEUTICALS. HOWEVER, DUE TO THE SHORT HALF-LIVES OF PET ISOTOPES (E.G., 20 MINUTES FOR C-11, 2 HOURS FOR F-18), THE ENTIRE PROCESS FROM CYCLOTRON TO RADIOPHARMACEUTICAL SYNTHESIS TO QUALITY CONTROL TO INJECTION, AND IMAGING MUST BE STREAMLINED TO ENSURE EFFICIENCY AND RADIOCHEMICAL YIELD. THE RADIOPHARMACY FACILITIES AT THE YALE SCHOOL OF MEDICINE (YSM) ARE HOUSED WITHIN THE YALE PET CORE WHICH OPERATES AS A REVENUE-NEUTRAL INTER-SERVICE PROVIDER OFFERING FULL PET STUDY SERVICES EXCLUSIVELY FOR RESEARCH. THE PET CORE SERVES INVESTIGATORS IN PSYCHIATRY, NEUROLOGY, CARDIOLOGY, ENDOCRINOLOGY, AND BASIC NEUROSCIENCE. INVESTIGATORS ARE PART OF A LARGE NIH-FUNDED COMMUNITY AT YALE AND THROUGHOUT NEW ENGLAND, AS WELL AS SEVERAL INSTITUTIONS NATIONALLY THROUGH CLINICAL TRIALS RECRUITING SUBJECTS IN THE YALE PET CORE. SINCE ITS INCEPTION IN 2006, THE PET CORE HAS GROWN RAPIDLY, PERFORMING PET IMAGING RESEARCH STUDIES IN HUMANS AND A VARIETY OF ANIMAL SPECIES. OVER 1,100 SCANS ARE PROJECTED FOR 2025. DESPITE A SIGNIFICANT INCREASE IN THE NUMBER OF SCANNERS AND EFFICIENCY IN THE PET CORE, RADIOCHEMISTRY PRODUCTION CAPABILITIES HAVE NOT GROWN ACCORDINGLY. CURRENTLY, THERE ARE 7 PET SCANNERS AVAILABLE FOR ROUTINE USE, WITH MORE EXPECTED TO BE INSTALLED SHORTLY, WHILE THE RADIOPHARMACY FACILITIES WERE ORIGINALLY DESIGNED TO SUPPORT RADIOTRACER PRODUCTION FOR 3 PET SCANNERS. TO OPERATE AVAILABLE PET SCANNERS AT FULL CAPACITY, THE PET CORE WILL REQUIRE A SUBSTANTIAL INCREASE TO THE EXISTING RADIOCHEMISTRY INFRASTRUCTURE. THIS WOULD SIGNIFICANTLY REDUCE THE WAITING TIME (4-6 WEEKS) TO PERFORM A PET SCAN. FURTHERMORE, A UNIQUE OPPORTUNITY EXISTS TO EXPAND AND UPDATE THE PET CORE FACILITIES TO BRING THE RADIOPHARMACY MANUFACTURING TO 21 CFR PART 212 CURRENT GOOD MANUFACTURING PRACTICE (CGMP) FOR PET DRUG PRODUCTION. SINCE THE RADIOCHEMISTRY AND RADIOPHARMACY FACILITIES HAVE NOT UNDERGONE A MAJOR REDESIGN SINCE 2006, A SIGNIFICANT UPGRADE IS NECESSARY. THIS WILL ENABLE THE PRODUCTION OF APPROVED COMPOUNDS IN THE AREAS OF ONCOLOGY, NEURODEGENERATION AND CARDIAC IMAGING, WHILE ENABLING SHIPPING RADIOPHARMACEUTICALS FOR HUMAN USE OUTSIDE THE YALE CAMPUS. MOST IMPORTANTLY, THE EXPANSION AND UPGRADES TO THE RADIOCHEMISTRY FACILITIES WILL ENHANCE THE INVESTIGATORS’ ABILITY TO EFFICIENTLY WORK ON THE DISCOVERY AND DEVELOPMENT OF NOVEL RADIOCHEMISTRY COMPOUNDS FOCUSED ON THE DETECTION, UNDERSTANDING, AND TREATMENT OF DISEASE AND STREAMLINE TRANSLATION TO RADIOPHARMACEUTICAL PRODUCTION. THE PET CORE MULTI-PHASE RENOVATION AND EXPANSION PROJECT WILL OCCUR WITHIN THE MAGNETIC RESONANCE RESEARCH CENTER BUILDING (MRC). THE REQUESTED C06 FUNDS WILL BE USED IN THREE PHASES TO: I) BUILD A NEW RADIOCHEMISTRY/RADIOPHARMACY/QC LAB CGMP SUITE, II) UPGRADE THE EXISTING RADIOCHEMISTRY LAB TO CGMP, AND III) CONVERT THE QC LAB TO A RESEARCH HOT CHEMISTRY LAB. THIS SCOPE WILL ACCELERATE DISCOVERY AND DEVELOPMENT OF NOVEL RADIOCHEMISTRY COMPOUNDS, ENABLE SHIPPING OF PET RADIOTRACERS TO OUTSIDE ENTITIES, REDUCE WAITING TIME FOR PET IMAGING AND MAXIMIZE YALE’S UNIQUE PET RESOURCES’ REACH AND ACCESSIBILITY.
Department of Health and Human Services
$7.6M
METABOLIC MARKERS AND PREDICTORS OF CHILDHOOD OBESITY
Department of Health and Human Services
$7.6M
TM INTERACTIONS IN MEMBRANE PROTEIN FOLDING AND FUNCTION
Department of Health and Human Services
$7.6M
CHEMISTRY PRINCIPLES APPLIED TO THE DEVELOPMENT OF NEW CATALYTIC C-H BOND FUNCTIONALIZATION METHODS FOR AMINE AND HETEROCYCLE PREPARATION AND TO THE DESIGN, SYNTHESIS AND USE OF NEW ENZYME INHIBITORS
Department of Health and Human Services
$7.5M
DIABETES MELLITUS AND DISORDERS OF METABOLISM
Department of Health and Human Services
$7.5M
OOCYTE DEVELOPMENT IN DROSOPHILA
Department of Health and Human Services
$7.5M
LARGE SCALE GENOME SEQUENCING AND INTEGRATIVE ANALYSES TO DEFINE GENOMIC PREDICTORS OF RECURRENT PREGNANCY LOSS - SUMMARY: RECURRENT PREGNANCY LOSS (RPL) OCCURS IN APPROXIMATELY 5% OF CLINICALLY RECOGNIZED PREGNANCY LOSSES. THE ETIOLOGY OF RPL IS NOT WELL CHARACTERIZED: AFTER EXCLUDING THE KNOWN ETIOLOGIES, APPROXIMATELY HALF OF WOMEN WITH RPL STILL HAVE NO IDENTIFIABLE CAUSE. THE FACT THAT RPL IS, IN FACT, RECURRENT SUGGESTS A STRONG GENETIC COMPONENT, HOWEVER THERE IS CURRENTLY A VERY LIMITED UNDERSTANDING OF THE GENOMIC CONTRIBUTIONS TO RPL. PREVIOUS STUDIES ARE TYPICALLY DEFICIENT IN THEIR DESIGN, LIMITED BY SMALL SAMPLE SIZE, INCOMPLETE CLINICAL PHENOTYPING AND/OR THE RECRUITMENT OF SINGLETONS ONLY. IN THIS PROPOSAL, WE PUT FORWARD OUR PLAN TO RECRUIT 1000 RIGOROUSLY-PHENOTYPED RPL TRIOS INCLUDING FROM DIVERSE AND UNDERREPRESENTED BACKGROUNDS ACROSS THE US AND TO APPLY WGS AND SOPHISTICATED VARIANT DETECTION AND INTERPRETATION METHODS DEVELOPED BY OUR LABS TO IDENTIFY PATHOGENIC AND LIKELY PATHOGENIC VARIANTS FOR RPL. WE WILL THEN PERFORM COMPREHENSIVE INTEGRATIVE DATA ANALYSES TO DEFINE THE GENETIC BASIS OF UNEXPLAINED RPL AND MAP THE GENES AND REGIONS OF THE CHROMOSOME THAT ARE ABSOLUTELY REQUIRED FOR HUMAN DEVELOPMENT AND A SUCCESSFUL PREGNANCY. OUR VARIANT INTERPRETATION PIPELINE INCLUDES CUTTING EDGE APPROACHES TO MAP LIKELY PATHOGENIC NONCODING AND STRUCTURAL VARIANTS RARELY ASSESSED IN ANY PREGNANCY LOSS STUDY. WE WILL ALSO PERFORM A PILOT RNA-SEQ STUDY TO ASSESS THE UTILITY OF THIS APPROACH FOR GENE DISCOVERY IN THE PREGNANCY LOSS SETTING. WE WILL FIRST LOOK FOR RECESSIVE PATHOGENIC VARIATION, INCLUDING COMPOUND HETEROZYGOSITY AND THEN TEST FOR MODELS FOR DE NOVO MOSAICISM, MITOCHONDRIAL MUTATIONS, REGULATORY NONCODING VARIATION AND OVERALL MUTATIONAL BURDEN. FROM THESE COMBINED ANALYSES, WE EXPECT TO UNCOVER MANY VARIANTS IN GENES AND REGIONS OF THE CHROMOSOME THAT ARE INTOLERABLE TO FUNCTIONAL VARIATION, WHICH WE DEFINE AS THE HUMAN INTOLEROME. WE WILL BUILD ON OUR PREVIOUS STUDIES TO MAP THE INTOLEROME BY COMBINING I) AVAILABLE DATA FROM ALL CLINICAL STUDIES TO DEFINE THE GENETIC ETIOLOGY OF UNEXPLAINED PREGNANCY LOSS, INCLUDING DATA GENERATED IN THIS PROPOSAL AND IN OUR PRIOR WORK, II) NETWORK-BASED APPROACHES TO PRIORITIZE VARIANTS GENES IMPORTANT FOR HUMAN DEVELOPMENT AND PREGNANCY, III) MOUSE (KOMP, DMDD/MGI) AND CELL LINE KNOCKOUT STUDIES IV) RARE AND COMMON DISEASE SEQUENCING STUDIES INCLUDING CENTERS FOR MENDELIAN GENOMICS (CMG), CENTER FOR COMMON DISEASE GENOMICS (CCDG) AND PEDIATRIC CARDIAC GENOMICS CONSORTIUM (PCGC), IV) EMERGING HUMAN PANGENOME STUDIES HPP, AND V) POPULATION-SCALE BIOBANK PROJECTS SUCH AS UK BIOBANK AND ALL OF US. WE WILL THEN CONFIRM THESE PREDICTIONS VIA COLLABORATOR-LED FUNCTIONAL STUDIES AND RETROSPECTIVE ANALYSES OF RPL FIRST LOSSES, SIBLINGS AND GRANDPARENTS. THE SHARING OF EARLY, UNPUBLISHED DATA FROM THE YALE CMG AND HPP ENABLED BY OUR LEADERSHIP IN THESE PROJECTS IS A SIGNIFICANT STRENGTH OF WHAT WILL BE BY FAR THE LARGEST AND MOST COMPREHENSIVE STUDY OF RPL PERFORMED TO DATE. OUR FINDINGS WILL TAKE GREAT STRIDES TOWARDS THE GOAL OF COMPREHENSIVELY MAPPING THE HUMAN INTOLEROME AND WILL FURTHER EXPAND AND REFINE THE EXPLORATORY SPACE IN WHICH TO INVESTIGATE THE GENES AND CHROMOSOMAL REGIONS ESSENTIAL FOR HUMAN DEVELOPMENT.
Department of Health and Human Services
$7.5M
ALCOHOL ASSOCIATED OUTCOMES AMONG HIV+/- AGING VETERANS
Department of Energy
$7.4M
TAS::89 0222::TAS - NUCLEAR PHYSICS-EXPERIMENTAL RESEARCH
Department of Health and Human Services
$7.3M
INTEGRATED FUNCTION/STRUCTURE IMAGE ANALYSIS IN AUTISM
Department of Health and Human Services
$7.3M
MOLECULAR MECHANISMS OF THE MATERNAL TO ZYGOTIC TRANSITION
Department of Health and Human Services
$7.3M
CHARACTERIZATION AND PREVENTION OF CHEMOTHERAPY-INDUCED DAMAGE TO OVARIAN RESERVE
Department of Health and Human Services
$7.3M
ANTIMALARIAL PHARMACOLOGY IN HIV COINFECTED CHILDREN AND PREGNANT WOMEN IN UGANDA
Department of State
$7.3M
THIS AWARD IS ISSUED FOR A PROGRAM TO SUPPORT BUILDING EFFECTIVE, RESILIENT, AND TRUSTED POLICE ORGANIZATIONS IN MEXICO.
Department of Health and Human Services
$7.2M
YALE DRUG ABUSE, ADDICTION, AND HIV RESEARCH SCHOLARS (YALE-DAHRS)
Department of Health and Human Services
$7.2M
PHASE II TRIAL OF HOKT3GAMMA 1 (ALA-ALA) IN TYPE 1 DIABETES
Department of Health and Human Services
$7.2M
SYNDECAN FUNCTION IN ENDOTHELIAL CELLS
Department of Health and Human Services
$7.2M
ADMINISTRATIVE SUPPLEMENT TO EXISTING NIH GRANT AND COOPERATIVE AGREEMENT
Department of Health and Human Services
$7.1M
GENETICS OF OPIOID DEPENDENCE
Department of Education
$7.1M
GAINING EARLY AWARENESS AND READINESS FOR UNDERGRADUATE PROGRAMS (GEAR UP PARTNERSHIP)
Department of Health and Human Services
$7.1M
LIVE IMAGING OF SKIN REGENERATION
Department of Health and Human Services
$7M
MENTAL HEALTH NEW ENGLAND TECHNOLOGY TRANSFER CENTER (MH-NETT)
Department of Health and Human Services
$7M
THE IDENTIFICATION AND CHARACTERIZATION OF GENETIC VARIANTS UNDERLYING CARDIOVASCULAR DISEASES
Department of Health and Human Services
$7M
PATHOGENESIS OF YOUTH ONSET PRE DIABETES AND TYPE 2 DIABETES.
Department of Health and Human Services
$7M
EVOLUTIONARY GENETICS OF TSETSE AND ITS SYMBIONTS
Department of Health and Human Services
$7M
YALE TMC FOR CELLULAR SENESCENCE IN LYMPHOID ORGANS - PROJECT SUMMARY CELL SENESCENCE IN HUMAN TISSUES IS AN IRREVERSIBLE CELL CYCLE ARREST STATE IN OTHERWISE PROLIFERATIVE CELLS, WHICH IS A HALLMARK OF AGING THAT ALTERS THE TISSUE ENVIRONMENTS VIA SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP) BUT MAY ALSO PLAY A BENEFICIAL ROLE IN TISSUE REMODELING, REGENERATION, AND WOUND HEALING. LYMPHOID ORGANS PLAY A VITAL ROLE IN HEMATOPOIESIS AND IMMUNE FUNCTION. HOW CELLULAR SENESCENCE IN THESE TISSUES IS ASSOCIATED WITH STRESS-INDUCED OR AGE-RELATED FUNCTIONAL IMPAIRMENT, WHAT TYPES OR SUBTYPES OF SENESCENT CELLS ARE PRESENT AND THEIR SPATIAL HETEROGENEITY AND HOW THESE CELLS IMPACT THE TISSUE ENVIRONMENTS REMAIN POORLY UNDERSTOOD, PRECLUDING THE DEVELOPMENT OF STRATEGIES TO TARGET SENESCENT CELLS TO IMPROVE HEALTHSPAN/LIFESPAN OR HARNESSING THESE CELLS OR SECRETED FACTORS TO PROMOTE TISSUE REMODELING AND REPAIR. A RECENT COMMENTARY PUBLISHED IN CELL BY NIH IDENTIFIED FIVE BROAD AREAS (ATLASES, IMAGING &VISUALIZATION, BIOMARKERS, MODEL SYSTEMS, PERTURBATION AND VALIDATION) THAT WOULD HELP PROPEL THE FIELD FORWARD. OUR APPLICATION WILL ASSEMBLE A MULTIDISCIPLINARY TEAM TO TACKLE ALL THESE AREAS AND SPECIFICALLY, AS A TISSUE MAPPING CENTER (TMC), WILL FOCUS ON GENERATING THE MOLECULAR AND CELLULAR MAPS OF CELLULAR SENESCENCE AND ASSOCIATED TISSUE ENVIRONMENTS IN 4 PRIMARY AND SECONDARY LYMPHOID ORGANS. SPECIFICALLY, IT WILL (A) COLLECT, ANALYZE, ANNOTATE, AND SHARE HIGH QUALITY NON-DISEASED HUMAN PRIMARY (BONE MARROW AND THYMUS) AND SECONDARY (TONSIL AND LYMPH NODE) LYMPHOID TISSUES, (2) DEVELOP AND DEPLOY A SUITE OF HIGH-RESOLUTION, HIGH-CONTENT AND HIGH-THROUGHPUT SINGLE- CELL & SPATIAL OMICS TECHNOLOGIES TO CHARACTERIZE THESE SPECIMENS AND PAIRED BIOFLUIDS, AND (3) PERFORM INTEGRATED INFORMATICS TO IDENTIFY BIOMARKERS OF SENESCENT CELL HETEROGENEITY AND TO CONSTRUCT COMPREHENSIVE MOLECULAR AND CELLULAR MAPS OF CELLULAR SENESCENCE AND ASSOCIATED ENVIRONMENTS IN THESE ORGANS. FOUR MAJOR BIOLOGICAL ANALYSIS PIPELINES ARE: (1) SINGLE-CELL HIGH-PLEX (>40) PROTEIN SECRETOME PROFILING, (2) SINGLE-CELL PROTEO-TRANSCRIPTOMIC SEQUENCING (SCCITE-SEQ), (3) SPATIAL PROTEO-TRANSCRIPTOMIC SEQUENCING AT CELLULAR LEVEL (DBIT-SEQ FOR CO-MAPPING WHOLE TRANSCRIPTOME AND A PANEL OF ~300 PROTEINS AT CELLULAR LEVEL WITH 10ΜM PIXEL SIZE), AND (4) SPATIAL MOLECULAR IMAGING (SMI) OF ~1,000 MOLECULAR TARGETS IN FFPE TISSUES AT SINGLE-MOLECULE SUBCELLULAR RESOLUTION. WITH THESE UNIQUE TOOLS, WE WILL (A) CHARACTERIZE FUNCTIONAL SASP HETEROGENEITY AND IDENTIFY BIOMARKERS OF SAPS IN DIFFERENT CELL TYPES, (B) CONSTRUCT MOLECULAR AND CELLULAR MAPS IN 4 HUMAN LYMPHOID TISSUES, AND (C) IDENTIFY BIOMARKERS OF CELLULAR SENESCENCE IN TISSUE AND THE ASSOCIATED ENVIRONMENTS, CONTRIBUTING TO THE RESOURCE BUILDING OF SENNET. SINCE THE IMMUNE FUNCTION IS CENTRAL TO THE PHYSIOLOGY OF ALL MAJOR ORGANS, OUR STUDY WILL PROVIDE INSIGHTS TO THE ROLE OF SENESCENT IMMUNE CELLS IN DEVELOPMENT, AGING, OR DISEASE IN OTHER ORGANS LIKE GUT, LUNG, LIVER, AND KIDNEY, REPRESENTING A STRONG SYNERGY WITHIN SENNET AND THE WIDER SCIENTIFIC COMMUNITY.
Department of Defense
$7M
THIS COOPERATIVE AGREEMENT SHALL BE PERFORMED IN ACCORDANCE WITH STATEMENT OF WORK, ENTITLED 'IDEAL: AN INTELLIGENT DESIGN ENVIRONMENT FOR ASYNCHRONO
Department of Health and Human Services
$7M
EMBED: PRAGMATIC TRIAL OF USER-CENTERED CLINICAL DECISION SUPPORT TO IMPLEMENT EMERGENCY DEPARTMENT-INITIATED BUPRENORPHINE FOR OPIOID USE DISORDER
Department of Health and Human Services
$7M
FUNCTIONAL OUTCOMES OF INFLAMMATORY BOWEL DISEASE ASSOCIATED VARIANTS
Department of Defense
$6.9M
RF CONTROL AND MEASUREMENT OF SUPERCONDUCTING QUBITS
National Science Foundation
$6.9M
BII: PREDICTING THE GLOBAL HOST-VIRUS NETWORK FROM MOLECULAR FOUNDATIONS -THE VIRAL EMERGENCE RESEARCH INITIATIVE BIOLOGY INTEGRATION INSTITUTE (VERENA BII) WILL INTEGRATE DATA AND BIOLOGICAL THEORY ACROSS THE FIELDS OF MICROBIOLOGY, IMMUNOLOGY, ECOLOGY, EVOLUTION, AND GLOBAL CHANGE BIOLOGY, WORKING TOWARDS A UNIFIED UNDERSTANDING THAT IMPROVES OUR ABILITY TO PREDICT VIRAL EMERGENCE. THE COVID-19 PANDEMIC HIGHLIGHTS A PRESSING NEED TO UNDERSTAND THE ECOLOGY AND EVOLUTION OF EMERGING VIRUSES. THESE GLOBAL DYNAMICS ARE DETERMINED FIRST AND FOREMOST BY THE GENETIC CODE OF BOTH VIRUSES AND THEIR HOSTS, AND BY MICROSCOPIC INTERACTIONS BETWEEN THE TWO AT THE LEVEL OF PROTEINS AND CELLS. HOWEVER, BIOLOGISTS FREQUENTLY STRUGGLE TO CONNECT THEORY ACROSS THESE SCALES. AT THE HEART OF THIS RESEARCH EFFORT IS AN OPEN CLEARINGHOUSE OF BIG DATA, CREATING NEW OPPORTUNITIES TO APPLY ARTIFICIAL INTELLIGENCE TO REAL-WORLD PROBLEMS. TO FOSTER A CORE SET OF DATA FLUENCY AND INTERDISCIPLINARY RESEARCH SKILLS, THE LIGHTHOUSE LEARNING COMMUNITY WILL TRAIN PARTICIPANTS AT EVERY CAREER STAGE IN THE BOUNDARY-SPANNING SCIENCE OF THE HOST-VIRUS NETWORK, INCLUDING MORE THAN 100 EARLY CAREER SCIENTISTS. UNDERGRADUATES WILL BE INTRODUCED TO BOTH BIOLOGY AND DATA SCIENCE THROUGH A COURSE-BASED UNDERGRADUATE RESEARCH EXPERIENCE IN ?THE FUNDAMENTALS OF DISEASE SURVEILLANCE,? WHILE GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS WILL EXPLORE THESE METHODS DEEPER THROUGH A BIOLOGY INTEGRATION WORKSHOP SERIES, INCLUDING A NEW SUMMER IN THE CAPITOL PROGRAM IN WASHINGTON, D.C. THIS COHORT OF EMERGING SCHOLARS WILL USE OPEN SOURCE MATERIALS, K-12 OUTREACH, AND DIGITAL MEDIA TO HARNESS PUBLIC INTEREST IN EMERGING DISEASES LIKE COVID-19, RAISING AWARENESS ABOUT KEY ISSUES WHILE SHARING THE IMPORTANCE OF BASIC BIOLOGICAL RESEARCH TO SAVE LIVES AND PROTECT ECOSYSTEMS. TO IDENTIFY THE MECHANISTIC AND MOLECULAR RULES OF LIFE THAT GOVERN HOST-VIRUS DYNAMICS AT PLANETARY SCALES, THE VERENA BII WILL LEVERAGE A UNIQUE MIX OF DATA SYNTHESIS, COMPUTATIONAL INNOVATION, FIELD SAMPLING, AND LABORATORY EXPERIMENTS TO IDENTIFY THE MOLECULAR UNDERPINNINGS OF HOST-VIRUS INTERACTIONS. AN UNPRECEDENTED COMPARATIVE STUDY OF THE CHIROPTERAN WITHIN-HOST ENVIRONMENT WILL GENERATE AND TEST HYPOTHESES ABOUT THE IMMUNOLOGICAL ADAPTATIONS THAT ALLOW BATS TO TOLERATE DEADLY VIRUSES. IN PARALLEL, MODEL-GUIDED EXPERIMENTS WILL MEASURE THE FEATURES OF THE INVERTEBRATE IMMUNE SYSTEM THAT PLAY THE GREATEST ROLE IN MOSQUITOES? COMPETENCE AS ARBOVIRAL VECTORS. TOGETHER, THESE MODEL SYSTEMS WILL ILLUMINATE THE HARD-CODED BASIS OF HOST-VIRUS COMPATIBILITY, SUPPORTING NEW MACHINE LEARNING METHODS TO PREDICT ECOLOGICAL AND EVOLUTIONARY NETWORKS AND ANTICIPATE GLOBAL RISKS OF VIRAL EMERGENCE IN A CHANGING CLIMATE. MORE BROADLY, THE VERENA BII WILL EXPAND AN EXISTING ROLE AS A HUB OF OPEN DATA, SOFTWARE, AND CYBERINFRASTRUCTURE FOR HOST-VIRUS INTERACTIONS, EXPERIMENTAL VIROLOGY, AND WILDLIFE DISEASE SURVEILLANCE. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE NOT PLANNED FOR THIS AWARD.
Department of Health and Human Services
$6.9M
MOLECULAR GENETIC ANALYSIS OF SALMONELLA CELL INVASION
Department of Health and Human Services
$6.9M
RESEARCH TRAINING PROGRAM IN SUBSTANCE ABUSE PREVENTION
Department of Health and Human Services
$6.9M
PARAMEDIC REFERRALS FOR INCREASED INDEPENDENCE AND DECREASED DISABILITY IN THE ELDERLY (PRIDE)
Department of Health and Human Services
$6.9M
DNA REPAIR IN CANCER BIOLOGY AND THERAPY
Department of Energy
$6.9M
INVESTIGATION OF NEUTRINO PROPERTIES AND FUNDAMENTAL SYMMETRIES AT YALE
Department of Health and Human Services
$6.9M
EXPRESSION OF ION CHANNELS IN THE AUDITORY SYSTEM
Department of Health and Human Services
$6.9M
CHRONIC DTH AND IFN-GAMMA IN HUMAN GRAFT ARTERIOSCLEROSIS
Department of Health and Human Services
$6.8M
NEURAL MECHANISMS OF ITCH
Department of Health and Human Services
$6.8M
FOOD CUES, STRESS, MOTIVATION FOR HIGHLY PALATABLE FOODS AND WEIGHT GAIN
Department of Defense
$6.8M
HIGH-RESOLUTION QUANTUM CONTROL OF CHEMICAL REACTIONS
Department of Health and Human Services
$6.7M
MEMBRANE PROPERTIES OF THE OHC SYSTEM
Department of Health and Human Services
$6.7M
SENSELAB: INTEGRATION OF MULTIDISCIPLINARY SENSORY DATA
Department of Health and Human Services
$6.6M
INJURY AND RECOVERY IN DEVELOPING BRAIN
Department of Health and Human Services
$6.6M
MOBILE HEALTH FOR IMPLEMENTATION OF HOME-BASED TB CONTACT INVESTIGATION IN UGANDA
Department of Health and Human Services
$6.6M
STRUCTURE-FUNCTION RELATIONSHIPS IN THE SPIROCHETAL FLAGELLAR MOTOR
Department of Health and Human Services
$6.6M
ENDOTHELIAL-TO-MESENCHYMA TRANSITION AND ATHEROSCLEROSIS
Department of Health and Human Services
$6.6M
IDENTIFYING METHAMPHETAMINE RISK VARIANTS BY EXTREME PHENOTYPE EXOME SEQUENCING
Department of Health and Human Services
$6.6M
VASCULAR RESEARCH TRAINING
Department of Health and Human Services
$6.6M
IN VIVO PATHWAY DISCOVERY IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
Department of Health and Human Services
$6.5M
YALE MURINE-TMC ON IMMUNE CELL SENESCENCE DERIVED INFLAMMATION - SUMMARY YALE-MURINE TMC (MTMC), THROUGH APPLICATION OF HIGH-CONTENT AND HIGH THROUGHPUT SINGLE-CELL AND SPATIAL OMICS TECHNOLOGIES, WE AIM TO ACCELERATE THE DISCOVERY OF SENESCENT BIOMARKERS, APPLY THEM TO MOUSE MODELS, AND GENERATE HYPOTHESES TO TEST MECHANISMS OF ORGANISMAL AGING. OUR PROPOSED UNBIASED ANALYSES WILL ALSO ANSWER THE QUESTION WHETHER SENESCENT CELLS (STROMAL OR HEMATOPOIETIC LINEAGE) EXIST IN SUFFICIENT QUANTITIES TO ALTER THE INFLAMMATORY LANDSCAPE AND BIOLOGY. YALE-MTMC WILL USE LINEAGE-MARKED MOUSE TO CLASSIFY TYPES OR SUBTYPES OF SENESCENT CELLS, THEIR SPATIAL HETEROGENEITY AND HOW THESE CELLS IMPACT THE TISSUE ENVIRONMENTS. YALE-MTMC WILL ASSEMBLE 1) A MULTIDISCIPLINARY TEAM TO GENERATE THE MOLECULAR AND CELLULAR MAPS OF CELLULAR SENESCENCE IN THYMUS, BONE MARROW, SPLEEN, PBMCS, MESENTERIC AND INGUINAL ADIPOSE TISSUE. 2) DEVELOP AND DEPLOY A SUITE OF HIGH-RESOLUTION, HIGH-CONTENT AND HIGH THROUGHPUT SINGLE-CELL AND SPATIAL OMICS TECHNOLOGIES TO CHARACTERIZE THESE SPECIMENS AND 3) PERFORM INTEGRATED INFORMATICS TO IDENTIFY BIOMARKERS OF SENESCENT CELL HETEROGENEITY AND TO CONSTRUCT COMPREHENSIVE MOLECULAR AND CELLULAR MAPS OF CELLULAR SENESCENCE AND INCLUDING AN I.V CD45 ANTIBODY LABELING/SORTING APPROACH TO STUDY TISSUE RESIDENT IMMUNE CELLS IN NON-LYMPHOID TISSUES. WE WILL UTILIZE THE ANALYSIS PLATFORMS ESTABLISHED THROUGH THE YALE HUMAN TMC TO ENABLE CROSS-SPECIES VERIFICATION OF BIOMARKERS. THREE MAJOR BIOLOGICAL ANALYSIS PIPELINES ARE: (A) MULTIPLEX IMAGING (MI) INCLUDING CODEX, IMC, AND SMI, COMPLEMENTED BY 3D LIGHT SHEET MICROSCOPY OF CLEARED TISSUES, (B) SINGLE CELL ANALYSIS (SCA) INCLUDING SCCITE-SEQ FOR PROTEIN AND MRNA PROFILING, CYTOF FOR HIGH-PLEX IMMUNOPHENOTYPING, AND SINGLE-CELL PROTEIN SECRETOME PROFILING TO MEASURE SASP HETEROGENEITY, AND (C) SPATIAL MULTI-OMICS SEQUENCING (SMOS) USING DBIT-BASED SPATIAL-CITE-SEQ FOR SPATIALLY RESOLVED PROTEO-TRANSCRIPTOMIC MAPPING AT GENOME SCALE. THE COMBINATION OF THESE PIPELINES ALLOWS FOR HIGHLY SENSITIVE AND SINGLE-CELL RESOLUTION MAPPING OF SENESCENT CELLS AND ASSOCIATED TISSUE ENVIRONMENTS. YALE-MTMC AIMS TO ASSEMBLE A MULTIDISCIPLINARY TEAM LED BY PI: DIXIT (DIRECTOR, YALE CENTER FOR RESEARCH ON AGING), AND MPI: MONTGOMERY (IMMUNOLOGIST, ASSOCIATE DEAN FOR SCIENTIFIC AFFAIRS) WITH CORE LEADS DR. FAN (BIOENGINEER), DR. KLUGER (INFORMATICS AND DATA ANALYTICS) AND KEY PERSONNEL DR. BOOTH (MOUSE PATHOLOGIST), DR. LUCAS, HABERMAN (IMMUNOLOGISTS, EXPERT IN PET STORE MOUSE MODEL, IMAGING) WITH IAB COMPOSED OF SCIENTIFIC LEADERS DRS. MEDZHITOV, IWASAKI AND RUDDLE. WE HAVE EXPERIENCE IN MANAGEMENT OF LARGE, MULTI-COMPONENT PROGRAMS AND PRIOR EXPERIENCE WITH GENERATING SIGNIFICANT HIGH-QUALITY IMAGING AND OMICS DATA AS PART OF A CONSORTIUM. A DEDICATED PROGRAM MANAGER WILL MANAGE AND COORDINATE ALL ACTIVITIES ACROSS THE CENTER AND WITH THE SENNET CONSORTIUM. COMPLEMENTARY AND MULTIDISCIPLINARY SCIENTIFIC EXPERTISE OF THE TEAM WILL TRANSLATE INTO THE COLLECTIVE CAPABILITY OF THE TMC TO FOSTER INTEGRATION OF MULTI- DIMENSIONAL, MULTIPARAMETER DATA GENERATION AND COORDINATION WITH SENNET AND OTHER TMCS FOR GREATER IMPACT
Department of Health and Human Services
$6.5M
BIPOLAR & SCHIZOPHRENIA CONSORTIUM FOR PARSING INTERMEDIATE PHENOTYPES
Department of Health and Human Services
$6.5M
IMMUNOHEMATOLOGY/TRANSFUSION MEDICINE RESEARCH TRAINING
Department of Health and Human Services
$6.5M
MOLECULAR BASIS FOR MEMBRANE LIPID HOMEOSTASIS
Department of Health and Human Services
$6.5M
TRANSCRIPTIONAL AND EPIGENETIC SIGNATURES OF HUMAN BRAIN DEVELOPMENT AND AUTISM
Department of Health and Human Services
$6.5M
FLUCTUATIONS IN IONIC CURRENT THROUGH MEMBRANE CHANNELS
Department of Health and Human Services
$6.5M
PREDOCTORAL PROGRAM IN BIOPHYSICS
Department of Health and Human Services
$6.5M
MECHANISMS OF CELL REGULATION AND MANIPULATION BY THE UBIQUITIN SYSTEM
Department of Health and Human Services
$6.5M
GLUCOREGULATORY HORMONE INTERACTIONS IN DIABETES
Department of Health and Human Services
$6.5M
1/2 CELL TYPE AND REGION-SPECIFIC REGULATORY NETWORKS IN HUMAN BRAIN DEVELOPMENT AND DISORDERS
Department of Health and Human Services
$6.5M
YALE SCOR ON GENDER-SENSITIVE TREATMENT FOR TOBACCO DEPENDENCE
Department of Health and Human Services
$6.5M
TREATMENT OF OBESITY AND BINGE EATING: BEHAVIORAL WEIGHT LOSS VERSUS STEPPED CARE
Department of Health and Human Services
$6.4M
NATURALLY-ACQUIRED AND VACCINE-MEDIATED IMMUNITY TO LEPTOSPIROSIS
Department of Health and Human Services
$6.4M
CHINESE HERBAL MEDICINE AS A NOVEL PARADIGM FOR CANCER CHEMOTHERAPY
Department of Health and Human Services
$6.4M
SIGNALING MECHANISMS AND FUNCTIONS RELATED TO PATHO-PHYSIOLOGY OF VASCULAR, LUNG AND BLOOD SYSTEMS
Source: Federal Audit Clearinghouse (fac.gov)
Total Audits
9
Clean Audits
9
Material Weakness
No
Noncompliance Issues
No
| Year | Status | Financial Report | Federal Expenditure | Low Risk | Accepted |
|---|---|---|---|---|---|
| 2025 | Clean | Unmodified (Clean) | $1B | Yes | 2026-01-16 |
| 2023 | Clean | Unmodified (Clean) | $882.9M | Yes | 2024-01-03 |
| 2022 | Clean | Unmodified (Clean) | $904.1M | Yes | 2023-01-12 |
| 2021 | Clean | Unmodified (Clean) | $759.5M | Yes | 2022-03-28 |
| 2020 | Clean | Unmodified (Clean) | $703.3M | Yes | 2021-03-29 |
| 2019 | Clean | Unmodified (Clean) | $697.8M | Yes | 2019-11-19 |
| 2018 | Clean | Unmodified (Clean) | $678.3M | Yes | 2019-03-25 |
| 2017 | Clean | Unmodified (Clean) | $652.3M | Yes | 2017-11-20 |
| 2016 | Clean | Unmodified (Clean) | $624M | Yes | 2016-12-05 |
Financial Report
Unmodified (Clean)
Federal Expenditure
$1B
Financial Report
Unmodified (Clean)
Federal Expenditure
$882.9M
Financial Report
Unmodified (Clean)
Federal Expenditure
$904.1M
Financial Report
Unmodified (Clean)
Federal Expenditure
$759.5M
Financial Report
Unmodified (Clean)
Federal Expenditure
$703.3M
Financial Report
Unmodified (Clean)
Federal Expenditure
$697.8M
Financial Report
Unmodified (Clean)
Federal Expenditure
$678.3M
Financial Report
Unmodified (Clean)
Federal Expenditure
$652.3M
Financial Report
Unmodified (Clean)
Federal Expenditure
$624M
Tax Year 2023 · Source: IRS e-Filed Form 990Schedule J available
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: GROUP
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2023IRS e-File | $6.8B | $1.4B | $6.2B | $55.2B | $45.2B |
| 2022IRS e-File | $6.3B | $1.3B | $5.6B | $54.3B | $43.9B |
| 2021 | $7.6B | $1.7B | $4.7B | $56.1B | $43.4B |
| 2020 | $5.6B |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2024 | 990 | IRS e-File | |
| 2023 | 990 | DataIRS e-File | PDF not yet published by IRSView Filing → |
| 2022 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2023)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2023)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Peter Salovey | Trustee & President | 50 | $2.3M | $0 | $117.8K | $2.5M |
| Alexander E Dreier | Sr VP For Institutional Affairs | 50 | $881.2K | $0 | $108.1K | $989.3K |
| Scott A Strobel | Provost | 50 | $887.9K | $0 | $64.5K | $952.4K |
| Jack F Callahan Jr | Sr VP For Operations | 50 | $829K | $0 | $84.4K | $913.4K |
| Joan E O'Neill | VP For Alumni Affairs & Development | 50 | $817.4K | $0 | $75.2K | $892.6K |
| Stephen C Murphy | VP For Finance & CFO | 50 | $596.6K | $0 | $146.8K | $743.4K |
| Jack Michael Bellamy | VP For Facilities, Campus Development & Sustainability | 50 | $663.5K | $0 | $42.4K | $705.9K |
| Kimberly M Goff-Crews | Secretary & VP For University Life | 50 | $530.7K | $0 | $50.4K | $581.1K |
| John Barden | VP For Technology And Campus Services | 50 | $472.6K | $0 | $75K | $547.6K |
| John Whelan | VP For Hr | 50 | $435.4K | $0 | $76.4K | $511.8K |
| Renee Kopkowski | VP For Communications | 50 | $393.1K | $0 | $59.7K | $452.8K |
Peter Salovey
Trustee & President
$2.5M
Hrs/Wk
50
Compensation
$2.3M
Related Orgs
$0
Other
$117.8K
Alexander E Dreier
Sr VP For Institutional Affairs
$989.3K
Hrs/Wk
50
Compensation
$881.2K
Related Orgs
$0
Other
$108.1K
Scott A Strobel
Provost
$952.4K
Hrs/Wk
50
Compensation
$887.9K
Related Orgs
$0
Other
$64.5K
Jack F Callahan Jr
Sr VP For Operations
$913.4K
Hrs/Wk
50
Compensation
$829K
Related Orgs
$0
Other
$84.4K
Joan E O'Neill
VP For Alumni Affairs & Development
$892.6K
Hrs/Wk
50
Compensation
$817.4K
Related Orgs
$0
Other
$75.2K
Stephen C Murphy
VP For Finance & CFO
$743.4K
Hrs/Wk
50
Compensation
$596.6K
Related Orgs
$0
Other
$146.8K
Jack Michael Bellamy
VP For Facilities, Campus Development & Sustainability
$705.9K
Hrs/Wk
50
Compensation
$663.5K
Related Orgs
$0
Other
$42.4K
Kimberly M Goff-Crews
Secretary & VP For University Life
$581.1K
Hrs/Wk
50
Compensation
$530.7K
Related Orgs
$0
Other
$50.4K
John Barden
VP For Technology And Campus Services
$547.6K
Hrs/Wk
50
Compensation
$472.6K
Related Orgs
$0
Other
$75K
John Whelan
VP For Hr
$511.8K
Hrs/Wk
50
Compensation
$435.4K
Related Orgs
$0
Other
$76.4K
Renee Kopkowski
VP For Communications
$452.8K
Hrs/Wk
50
Compensation
$393.1K
Related Orgs
$0
Other
$59.7K
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Matthew S T Mendelsohn | Chief Investment Officer | 50 | $2.3M | $0 | $2.1M | $4.4M |
| Timothy R Sullivan | Sr Director Of Private Equity | 50 | $2.1M | $0 | $78.4K | $2.1M |
| Alex Hetherington | Managing Director, Investments | 50 | $1.8M |
Matthew S T Mendelsohn
Chief Investment Officer
$4.4M
Hrs/Wk
50
Compensation
$2.3M
Related Orgs
$0
Other
$2.1M
Timothy R Sullivan
Sr Director Of Private Equity
$2.1M
Hrs/Wk
50
Compensation
$2.1M
Related Orgs
$0
Other
$78.4K
Alex Hetherington
Managing Director, Investments
$1.8M
Hrs/Wk
50
Compensation
$1.8M
Related Orgs
$0
Other
$73K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Ann Miura-Ko | Trustee | 5 | $0 | $0 | $0 | $0 |
| Carlos R Moreno | Trustee | 5 | $0 | $0 | $0 | $0 |
| Catharine B Hill | Trustee | 5 | $0 | $0 | $0 | $0 |
| David A Thomas | Trustee | 5 | $0 | $0 | $0 | $0 |
| David Sze | Trustee | 5 | $0 | $0 | $0 | $0 |
| Edward Miner Ned Lamont Jr | Trustee (ex-officio) |
Ann Miura-Ko
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Carlos R Moreno
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Catharine B Hill
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Individuals who previously served as officers or key employees.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Alexander C Banker | Former Director Of Investments | 50 | $1.6M | $0 | $79.6K | $1.7M |
| Pericles Lewis | Former VP For Global Strategy | 50 | $539.8K | $0 | $127.2K | $666.9K |
| Dean J Takahashi | Former Sr Director, Investments | 50 | $540.7K |
Alexander C Banker
Former Director Of Investments
$1.7M
Hrs/Wk
50
Compensation
$1.6M
Related Orgs
$0
Other
$79.6K
Pericles Lewis
Former VP For Global Strategy
$666.9K
Hrs/Wk
50
Compensation
$539.8K
Related Orgs
$0
Other
$127.2K
Dean J Takahashi
Former Sr Director, Investments
$593.7K
Hrs/Wk
50
Compensation
$540.7K
Related Orgs
$0
Other
$53K
| $1.4B |
| $4.6B |
| $44.2B |
| $31B |
| 2019 | $5.6B | $1.3B | $4.3B | $40.5B | $30.9B |
| 2018 | $5.1B | $1B | $4.1B | $39.1B | $30.9B |
| 2017 | $4.7B | $1.1B | $3.9B | $36.6B | $28.3B |
| 2016 | $4.8B | $963.2M | $3.7B | $34.1B | $25.8B |
| 2015 | $5.5B | $910.8M | $3.5B | $34.1B | $26.7B |
| 2014 | $4.5B | $878.4M | $3.4B | $32B | $25.1B |
| 2013 | $3.7B | $846.5M | $3.3B | $28.9B | $21.9B |
| 2012 | $3.6B | $864M | $3.1B | $28.3B | $20.1B |
| 2011 | $3.5B | $1.2B | $3B | $27.8B | $20.6B |
| 2021 | 990 | Data |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| $0 |
| $73K |
| $1.8M |
| John Ricotta | Managing Director, Investments | 50 | $1.7M | $0 | $75.2K | $1.8M |
| Murat Gunel | Chair, Neurosurgery | 50 | $1.7M | $0 | $87.6K | $1.8M |
| Amelia Chivetta | Managing Director, Investments | 50 | $1.7M | $0 | $52K | $1.7M |
| Nancy J Brown | Dean, School Of Medicine | 50 | $1.1M | $0 | $58.3K | $1.2M |
John Ricotta
Managing Director, Investments
$1.8M
Hrs/Wk
50
Compensation
$1.7M
Related Orgs
$0
Other
$75.2K
Murat Gunel
Chair, Neurosurgery
$1.8M
Hrs/Wk
50
Compensation
$1.7M
Related Orgs
$0
Other
$87.6K
Amelia Chivetta
Managing Director, Investments
$1.7M
Hrs/Wk
50
Compensation
$1.7M
Related Orgs
$0
Other
$52K
Nancy J Brown
Dean, School Of Medicine
$1.2M
Hrs/Wk
50
Compensation
$1.1M
Related Orgs
$0
Other
$58.3K
| — |
| $0 |
| $0 |
| $0 |
| $0 |
| Fred Krupp | Trustee | 5 | $0 | $0 | $0 | $0 |
| Gina R Boswell | Trustee | 5 | $0 | $0 | $0 | $0 |
| Joshua Bekenstein | Trustee | 5 | $0 | $0 | $0 | $0 |
| Joshua L Steiner | Trustee | 5 | $0 | $0 | $0 | $0 |
| Marta L Tellado | Trustee | 5 | $0 | $0 | $0 | $0 |
| Maryana Iskander | Trustee | 5 | $0 | $0 | $0 | $0 |
| Maurie Mcinnis | Trustee (through 5/29/24) | 5 | $0 | $0 | $0 | $0 |
| Michael J Cavanagh | Trustee | 5 | $0 | $0 | $0 | $0 |
| Michael Warren | Trustee | 5 | $0 | $0 | $0 | $0 |
| Neal S Wolin | Trustee | 5 | $0 | $0 | $0 | $0 |
| Susan Bysiewicz | Trustee (ex-officio) | — | $0 | $0 | $0 | $0 |
| William E Kennard | Trustee | 5 | $0 | $0 | $0 | $0 |
David A Thomas
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
David Sze
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Edward Miner Ned Lamont Jr
Trustee (ex-officio)
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Fred Krupp
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Gina R Boswell
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Joshua Bekenstein
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Joshua L Steiner
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Marta L Tellado
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Maryana Iskander
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Maurie Mcinnis
Trustee (through 5/29/24)
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Michael J Cavanagh
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Michael Warren
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Neal S Wolin
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Susan Bysiewicz
Trustee (ex-officio)
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
William E Kennard
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
| $0 |
| $53K |
| $593.7K |
| Benjamin Polak | Former Provost | 50 | $496K | $0 | $63.8K | $559.8K |
| Robert J Alpern | Former Dean, School Of Medicine | 50 | $344.4K | $0 | $39.8K | $384.2K |
| Karen Peart | Former Interim VP For Communications | 50 | $238.6K | $0 | $38.8K | $277.4K |
Benjamin Polak
Former Provost
$559.8K
Hrs/Wk
50
Compensation
$496K
Related Orgs
$0
Other
$63.8K
Robert J Alpern
Former Dean, School Of Medicine
$384.2K
Hrs/Wk
50
Compensation
$344.4K
Related Orgs
$0
Other
$39.8K
Karen Peart
Former Interim VP For Communications
$277.4K
Hrs/Wk
50
Compensation
$238.6K
Related Orgs
$0
Other
$38.8K